var title_f36_58_37792="Hurler brain MRI lateral";
var content_f36_58_37792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral T1-weighted MR cranial image showing severe hydrocephalus in a child with Hurler syndrome. The temporal horn of the lateral ventricle is dialated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37792=[""].join("\n");
var outline_f36_58_37792=null;
var title_f36_58_37793="Operative hysteroscope";
var content_f36_58_37793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    In-line operative hysteroscope with semirigid scissors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37793=[""].join("\n");
var outline_f36_58_37793=null;
var title_f36_58_37794="Ecological fallacy";
var content_f36_58_37794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Ecological fallacy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypothetical relationships between age and treatment effect both within trials (represented by the solid lines) and between trials (represented by the circles, which indicate the study means, and the dashed lines, which indicate the regression lines).",
"    <br>",
"     In the top example, individual studies demonstrate an association between age and treatment effect, but the association appears to be lost when looking only at the mean values across studies. Alternatively, in the bottom example, individual studies demonstrate no association between age and treatment effect. However, possibly due to chance or confounding, an apparent association is seen across the mean values of studies.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from: Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37794=[""].join("\n");
var outline_f36_58_37794=null;
var title_f36_58_37795="Subcorneal pustular dermatosis - histopathology";
var content_f36_58_37795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subcorneal neutrophilic pustule is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37795=[""].join("\n");
var outline_f36_58_37795=null;
var title_f36_58_37796="Juvenile plantar dermatosis";
var content_f36_58_37796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile plantar dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37796=[""].join("\n");
var outline_f36_58_37796=null;
var title_f36_58_37797="Heart attack symptoms women PI";
var content_f36_58_37797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Heart attack symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 703px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the main symptoms of a heart attack. People who are having a heart attack often have only some of these symptoms. The pain, pressure, and discomfort caused by a heart attack mostly affect the left side of the body (shown in darker red) but can also affect the right. If you think you are having a heart attack, call 9-1-1 for an ambulance. Do not try to get yourself to the hospital.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37797=[""].join("\n");
var outline_f36_58_37797=null;
var title_f36_58_37798="Artemether and lumefantrine: Drug information";
var content_f36_58_37798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Artemether and lumefantrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/57/8085?source=see_link\">",
"    see \"Artemether and lumefantrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/30/15846?source=see_link\">",
"    see \"Artemether and lumefantrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7695214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coartem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7710147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7725928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of uncomplicated malaria:",
"     </b>",
"     Three-day schedule: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients 25 to &lt;35 kg: Three tablets at hour 0 and hour 8 on the first day, then 3 tablets twice daily on day 2 and day 3 (total of 18 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients &ge;35 kg: Four tablets at hour 0 and hour 8 on the first day, then 4 tablets twice daily on day 2 and day 3 (total of 24 tablets per treatment course)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7725883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/30/15846?source=see_link\">",
"      see \"Artemether and lumefantrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of uncomplicated malaria:",
"     </b>",
"     Three-day schedule: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2 months to &le;16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 to &lt;15 kg: One tablet at hour 0 and hour 8 on the first day, then 1 tablet twice daily on day 2 and day 3 (total of 6 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15 to &lt;25 kg: Two tablets at hour 0 and hour 8 on the first day, then 2 tablets twice daily on day 2 and day 3 (total of 12 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     25 to &lt;35 kg: Three tablets at hour 0 and hour 8 on the first day, then 3 tablets twice daily on day 2 and day 3 (total of 18 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;35 kg: Four tablets at hour 0 and hour 8 on the first day, then 4 tablets twice daily on day 2 and day 3 (total of 24 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7726684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing:",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7726685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7726686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7726707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coartem&reg;: Artemether 20 mg and lumefantrine 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7725447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7726705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a full meal for best absorption. For patients unable to swallow tablets: Crush tablet and mix with 5-10 mL of water. Administer to patient. Rinse container with water and administer contents to the patient. The crushed mixture should be followed with food/drink if possible. Repeat dose if vomiting occurs within 2 hours of administration; for persistent vomiting, explore alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7710149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute, uncomplicated malaria infections due to",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     , including geographical regions where chloroquine resistance has been reported",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7725706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitation (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (adults 56%; children 13%), dizziness (adults 39%; children 4%), fever (25% to 29%), chills (adults 23%; children 5%), sleep disturbances (22%), fatigue (adults 17%; children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Anorexia (adults 40%; children 13%), nausea (adults 26%; children 5%), vomiting (17% to 18%), abdominal pain (adults 17%; children 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (adults 38%; children 5%), arthralgia (adults 34%; children 3%), myalgia (adults 32%; children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (adults 6%; children 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (5%), malaise (3%), vertigo (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (4%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Splenomegaly (9%), diarrhea (7% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (4% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatomegaly (6% to 9%), AST increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Rhinitis (4%), nasopharyngitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;3% (Limited to important or life-threatening): Acrodermatitis, angioedema, agitation, ALT increased, asthma, ataxia, back pain, bronchitis, bullous skin eruption, conjunctivitis, constipation, clonus, dyspepsia, dysphagia, eosinophilia, fine motor delay, gait disturbance, hearing loss, hematocrit decreased, hematuria, hyper-reflexia, hypersensitivity reactions, hypoesthesia, hypokalemia, impetigo, infection (viral/bacterial/parasitic), leukocytosis, leukopenia, lymphocyte morphology abnormal, mood swings, nystagmus, peptic ulcer, pharyngolaryngeal pain, proteinuria, QT prolongation, tinnitus, thrombocytopenia, thrombocytosis, tremor, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7725582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to artemether, lumefantrine, or any component of the formulation; concurrent use with strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St John&rsquo;s wort)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7725583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: Use associated with prolonging the QT interval; avoid use in patients at risk for QT prolongation, including patients with a history of long QT syndrome, family history of congenital QT prolongation or sudden death, symptomatic arrhythmias, clinically relevant bradycardia, severe heart disease, known hypokalemia, hypomagnesemia or concurrent administration of antiarrhythmics (eg, Class Ia or III), drugs metabolized by CYP2D6 known to have cardiac effects (eg, flecainide, tricyclic antidepressants), or other drugs known to prolong the QT interval (eg, antipsychotics, antidepressants, macrolides, fluoroquinolones, triazole antifungals, or cisapride).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use caution in patients with severe renal impairment; has not been adequately studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drugs metabolized by CYP enzymes: Use with caution in patients receiving CYP3A4 inhibitors, substrates, or inducers as loss of concomitant drug efficacy or QT prolongation may occur. Use contraindicated in patients receiving strong CYP3A4 inducers. Avoid use in patients receiving medications metabolized by CYP2D6 as plasma concentrations of theses coadministered medications may increase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drugs that prolong the QT interval: Do not use within 1 month of halofantrine (not available in the U.S.) due to the potential additive effects on the QT interval. Concomitant use of agents that prolong the QT interval or promote hypokalemia or hypomagnesemia should be avoided; consider alternative therapy. After discontinuation of artemether/lumefantrine, drugs that prolong the QT interval, including quinidine and quinine, should be used with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mefloquine: If mefloquine is administered prior to lumefantrine, decreased lumefantrine exposure may occur due to mefloquine-induced decreased bile production; encourage food consumption and monitor efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Duplicate therapy: Antimalarials should not be given concomitantly unless there is no other treatment option.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hormonal contraceptives: Concomitant use may decrease effectiveness of hormonal contraceptives; patients should be advised to use additional nonhormonal contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not indicated for the treatment of severe or complicated malaria or for the prevention of malaria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Recrudescence: In the event of disease reappearance after a quiescent period, patients should be treated with a different antimalarial drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7734090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: Artemether may enhance the adverse/toxic effect of Antimalarial Agents.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May enhance the adverse/toxic effect of Lumefantrine. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Artemether may decrease the serum concentration of Contraceptives (Estrogens).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Artemether may decrease the serum concentration of Contraceptives (Progestins).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: Lumefantrine may enhance the QTc-prolonging effect of Halofantrine.  Management: Halofantrine and lumefantrine (as artemether-lumefantrine combination) should not be used within 1 month of each other.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7725713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal). Administration with grapefruit juice may result in increased concentrations of artemether and/or lumefantrine and potentiate QT prolongation. Management: Administer with a full meal for maximal absorption. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7725577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7725578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated increased fetal resorption and postimplantation loss during the period of organogenesis. Safety data from an observational pregnancy study included 500 pregnant women exposed to artemether/lumefantrine and did not show an increased in adverse outcomes or teratogenic effects over background rate. Approximately one-third of these patients were in the third trimester. Efficacy has not been established in pregnant patients. Treatment failures with standard doses have been reported in pregnant women in areas where drug resistant parasites are prevalent. This may be attributed to lower serum concentration of both artemether and lumefantrine in this population (McGready, 2008). Use during pregnancy only if potential benefit justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7725580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7725581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The benefits of breast-feeding to mother and infants should be weighed against the potential risk from infant exposure to artemether and lumefantrine.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7725716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a full meal for best absorption. Patients should be encouraged to take with a meal as soon as food can be tolerated. Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be great.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Coartem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-120 mg (24): $100.87",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10335325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patients for adequate food consumption (to ensure absorption and efficacy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amblum (PK);",
"     </li>",
"     <li>",
"      Coartem (ID, PE, PH, TH);",
"     </li>",
"     <li>",
"      Exafal (PK);",
"     </li>",
"     <li>",
"      Riamet (AT, AU, BE, CH, CZ, DE, FR, GB, GR, MY, NL, NZ, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7726703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A coformulation of artemether and lumefantrine with activity against",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     . Artemether and major metabolite dihydroartemisinin (DHA) are rapid schizontocides with activity attributed to the endoperoxide moiety common to each substance. Artemether inhibits an essential calcium adenosine triphosphatase. The exact mechanism of lumefantrine is unknown, but it may inhibit the formation of &beta;-hematin by complexing with hemin. Both artemether and lumefantrine inhibit nucleic acid and protein synthesis. Artemether rapidly reduces parasite biomass and lumefantrine eliminates residual parasites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7725803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Artemether: Rapid; Lumefantrine: Initial absorption at 2 hours; enhanced with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Artemether: 95%; Dihydroartemisinin (DHA): 47% to 76%; Lumefantrine: 99.7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Artemether is hepatically metabolized to an active metabolite, dihydroartemisinin (DHA), catalyzed predominately by CYP3A4/5 and to a lesser extent by CYP2B6, CYP2C9 and CYP2C19. The artemether/DHA AUC ratio is 1.2 after 1 dose and 0.3 after 6 doses which may indicate autoinduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lumefantrine is hepatically metabolized to desbutyl-lumefantrine by CYP3A4.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Artemether: 1-2 hours; DHA: 2 hours; Lumefantrine: 72-144  hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Artemether: ~2 hours; Lumefantrine: ~6-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alecrim MG, Lacerda MV, Mour&atilde;o MP, et al, &ldquo;Successful Treatment of",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Malaria With a Six-Dose Regimen of Artemether-Lumefantrine Versus Quinine-Doxycycline in the Western Amazon Region of Brazil,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2006, 74(1):20-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/58/37798/abstract-text/16407341/pubmed\" id=\"16407341\" target=\"_blank\">",
"        16407341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makanga M, Premji Z, Falade C, et al, &ldquo;Efficacy and Safety of the Six-Dose Regimen of Artemether-Lumefantrine in Pediatrics With Uncomplicated",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Malaria: a Pooled Analysis of Individual Patient Data,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2006, 74(6):991-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/58/37798/abstract-text/16760509/pubmed\" id=\"16760509\" target=\"_blank\">",
"        16760509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGready R, Tan SO, Ashley EA, et al, &ldquo;A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Treatment in Pregnancy,&rdquo;",
"      <i>",
"       PLoS Med",
"      </i>",
"      , 2008, 5(12):e253.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/58/37798/abstract-text/19265453/pubmed\" id=\"19265453\" target=\"_blank\">",
"        19265453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omari AA, Gamble C, and Garner P, &ldquo;Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated",
"      <i>",
"       Falciparum",
"      </i>",
"      Malaria,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2005, Issue 4, Art. No.: CD005564.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/58/37798/abstract-text/16235412/pubmed\" id=\"16235412\" target=\"_blank\">",
"        16235412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toovey S and Jamieson A, &ldquo;Audiometric Changes Associated With the Treatment of Uncomplicated",
"      <i>",
"       Falciparum",
"      </i>",
"      malaria With Co-Artemether,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 2004, 98(5):261-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/58/37798/abstract-text/15109547/pubmed\" id=\"15109547\" target=\"_blank\">",
"        15109547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;World Health Organization Guidelines for the Treatment of Malaria,&rdquo; Available at  file://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9066 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-E0F60D9195-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37798=[""].join("\n");
var outline_f36_58_37798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695214\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710147\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725928\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725883\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726684\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726685\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726686\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726707\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725447\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726705\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710149\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725706\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725582\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725583\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298772\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7734090\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725713\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725577\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725578\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725580\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725581\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725716\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321948\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10335325\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390222\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726703\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725803\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9066\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9066|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/57/8085?source=related_link\">",
"      Artemether and lumefantrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/30/15846?source=related_link\">",
"      Artemether and lumefantrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_58_37799="Superior mesenteric artery syndrome";
var content_f36_58_37799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Superior mesenteric artery syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Sherry Scovell, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Allen Hamdan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37799/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/58/37799/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior mesenteric artery syndrome is an unusual cause of proximal intestinal obstruction. It has been referred to by a variety of other names including Cast syndrome, Wilkie syndrome, arteriomesenteric duodenal obstruction, and chronic duodenal ileus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The syndrome is characterized by compression of the third portion of the duodenum due to narrowing of the space between the superior mesenteric artery and aorta and is primarily attributed to loss of the intervening mesenteric fat pad.",
"   </p>",
"   <p>",
"    There remains some controversy surrounding a diagnosis of superior mesenteric artery syndrome since symptoms do not always correlate well with abnormal anatomic findings on radiologic studies, and symptoms may not resolve completely following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Furthermore, the diagnosis may be confused with other anatomic or motility-related causes of duodenal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of superior mesenteric artery syndrome will be reviewed here. The management of bowel obstruction is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third portion of the duodenum passes between the aorta and the superior mesenteric artery (",
"    <a class=\"graphic graphic_figure graphicRef74899 \" href=\"mobipreview.htm?2/39/2678\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61740 \" href=\"mobipreview.htm?28/21/29021\">",
"     image 1",
"    </a>",
"    ). The duodenum typically crosses anterior to the aorta at the level of the third lumbar vertebral body suspended by its attachment to the ligament of Treitz.",
"   </p>",
"   <p>",
"    The superior mesenteric artery arises from the anterior aspect of the aorta at the level of the L1 vertebral body. It is enveloped in fatty and lymphatic tissue and extends in a caudal direction at an acute angle into the mesentery. In the majority of patients, the normal angle between the superior mesenteric artery and the aorta is between 38 and 65&ordm; due, in part, to the mesenteric fat pad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/6\">",
"     6",
"    </a>",
"    ]. This angle correlates with body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/7\">",
"     7",
"    </a>",
"    ]. The aorto-mesenteric distance is normally 10 to 28 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In superior mesenteric artery syndrome, the angle can be narrowed to as low as 6&ordm; with the aorto-mesenteric distances as low as 2 mm which minimizes the space between the superior mesenteric artery and aorta potentially leading to duodenal compression (",
"    <a class=\"graphic graphic_figure graphicRef74899 \" href=\"mobipreview.htm?2/39/2678\">",
"     figure 1",
"    </a>",
"    ). The left renal vein may also be compressed which can result in nutcracker syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H23#H23\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Rare conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42646666\">",
"    <span class=\"h1\">",
"     PATIENTS AT RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors can decrease the acuity of the angle between the aorta and superior mesenteric artery. The most common is significant weight loss leading to loss of the mesenteric fat pad as a consequence of medical disorders, psychological disorders or surgery. Anatomic abnormalities (congenital or acquired) can also contribute.",
"   </p>",
"   <p>",
"    Superior mesenteric artery syndrome is most commonly associated with severe, debilitating illnesses, such as malignancy, malabsorption syndromes, AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/13\">",
"     13",
"    </a>",
"    ] and burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/14\">",
"     14",
"    </a>",
"    ]. It has also been described in a variety of other disorders associated with extreme weight loss including bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/15-18\">",
"     15-18",
"    </a>",
"    ], spinal cord injury, paraplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/19\">",
"     19",
"    </a>",
"    ], drug abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/20\">",
"     20",
"    </a>",
"    ], prolonged bed rest and anorexia nervosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss is not responsible for all cases. In younger patients, superior mesenteric artery syndrome is most commonly described following corrective spinal surgery for scoliosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/8,25-28\">",
"     8,25-28",
"    </a>",
"    ]. This procedure lengthens the spine cranially displacing the superior mesenteric artery origin, decreasing the mesenteric artery&rsquo;s lateral mobility and reducing the acuteness of the aorto-mesenteric angle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/29\">",
"     29",
"    </a>",
"    ]. Under this circumstance, it may be referred to as &lsquo;cast syndrome&rsquo;. Other surgeries may also be complicated by the development of superior mesenteric artery syndrome due to distortion of normal anatomy such as esophagectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, a patient may have a congenitally short ligament of Treitz suspending the duodenum in an abnormally cephalad position. A case report of identical twins with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/31\">",
"     31",
"    </a>",
"    ] and another case diagnosed in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/32\">",
"     32",
"    </a>",
"    ] suggest there may be a genetic predisposition in some patients. The origin of the superior mesenteric artery may also be abnormally low.",
"   </p>",
"   <p>",
"    There have been several reported cases of superior mesenteric artery syndrome coexisting with celiac axis compression syndrome. One report documented a patient with celiac axis compression, which was believed to be the cause of superior mesenteric artery syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/43/27316?source=see_link\">",
"     \"Celiac artery compression syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present acutely (such as following surgery) or more insidiously with progressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/3\">",
"     3",
"    </a>",
"    ]. In both cases, symptoms are consistent with proximal small bowel obstruction. Patients with mild obstruction may have only postprandial epigastric pain and early satiety, while those with more advanced obstruction may have severe nausea, bilious emesis and weight loss. Patients may also have symptoms of reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms may be relieved when patient is lying prone, in the left lateral decubitus, or in a knee-chest position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/2\">",
"     2",
"    </a>",
"    ]. These positions remove tension from the mesentery and superior mesenteric artery opening the space between the superior mesenteric artery and aorta. &nbsp;",
"   </p>",
"   <p>",
"    Findings on physical examination are nonspecific but can include abdominal distension, a succussion splash, and high-pitched bowel sounds. Laboratory examination can be normal or, in patients with severe vomiting, significant electrolyte abnormalities may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of metabolic alkalosis\", section on 'Gastrointestinal hydrogen loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis is often delayed and may result in significant complications including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatalities due to electrolyte abnormalities",
"     </li>",
"     <li>",
"      Fatalities due to gastric perforation",
"     </li>",
"     <li>",
"      Gastric pneumatosis and portal venous gas",
"     </li>",
"     <li>",
"      Formation of an obstructing duodenal bezoar",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42647470\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of superior mesenteric artery syndrome includes other causes of bowel obstruction as well as diseases associated with duodenal dysmotility (and \"megaduodenum\") including diabetes mellitus, collagen vascular diseases, scleroderma, and chronic idiopathic intestinal pseudo-obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional causes of dyspepsia and reflux should be considered in patients with nonspecific symptoms and equivocal radiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a significant smoking history or other risk factors for atherosclerosis who have symptoms of chronic food intolerance associated with weight loss are more likely to have chronic mesenteric ischemia, a condition that is unlikely to be confused with superior mesenteric artery syndrome. Patients with chronic mesenteric ischemia usually have reproducible pain with eating and will not have obstructive symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high index of suspicion is required since symptoms can be nonspecific. A diagnosis of superior mesenteric artery syndrome is often a diagnosis of exclusion. If not already performed, patients should undergo judicious testing for other disorders that can cause similar symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation begins with plain abdominal films and radiography with oral contrast. These studies may be diagnostic in patients for whom there is heightened suspicion based upon the clinical setting. Additional testing may be needed for those patients in whom the diagnosis remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42647589\">",
"    <span class=\"h2\">",
"     Plain abdominal films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation should begin with abdominal radiographs. Although plain films are frequently nonspecific, they may reveal findings suggestive of proximal small bowel obstruction such as gastric distension, dilation of the proximal duodenum, and, occasionally, an abrupt vertical cutoff of air in the third portion of the duodenum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42647596\">",
"    <span class=\"h2\">",
"     Oral contrast studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal series usually demonstrate marked delay in passage of the contrast from the duodenum into the more distal small bowel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74949 graphicRef56017 \" href=\"mobipreview.htm?33/47/34546\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/3\">",
"     3",
"    </a>",
"    ]. Passage of contrast typically halts abruptly at the third portion of the duodenum. The proximal duodenum and stomach are dilated and show prolonged retention of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    . Similar findings can be seen with computed tomography (CT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasound &ndash; A noninvasive method to evaluate the mesenteric artery anatomy is using transabdominal ultrasound, which can identify and measure the aorto-mesenteric angle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80453 \" href=\"mobipreview.htm?12/25/12693\">",
"       image 3",
"      </a>",
"      ). Positional maneuvers not typically performed with routine examination may identify alterations in the aorto-mesenteric angle when the patient is in the lateral decubitus position or even standing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. The advantage of ultrasound is its low cost. Endoscopic ultrasound has also been used to demonstrate the anatomic abnormalities associated with superior mesenteric artery syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arteriography &ndash; Conventional arteriography was traditionally performed simultaneously with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      contrast radiography to demonstrate the superior mesenteric artery superimposed upon the barium-filled duodenum. Lateral mesenteric arteriography demonstrates the narrowing of the aorto-mesenteric angle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61740 \" href=\"mobipreview.htm?28/21/29021\">",
"       image 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Computed tomographic (CT) and magnetic resonance (MR) arteriography have largely replaced conventional arteriography since they are noninvasive and provide additional anatomic detail such as the amount of intra-abdominal and retroperitoneal fat (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77492 graphicRef76655 \" href=\"mobipreview.htm?22/2/22564\">",
"       image 4A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. However, arteriography may be needed if a diagnosis remains unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42647642\">",
"    <span class=\"h2\">",
"     Diagnostic imaging criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the following criteria should be present on imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/3,37,38\">",
"     3,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duodenal obstruction with an abrupt cutoff in the third portion and active peristalsis.",
"     </li>",
"     <li>",
"      An aorto-mesenteric artery angle of &le;25&deg; is the most sensitive measure of diagnosis, particularly if the aorto-mesenteric distance is &le;8 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High fixation of the duodenum by the ligament of Treitz, abnormally low origin of the superior mesenteric artery or anomalies of the superior mesenteric artery. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONSERVATIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of conservative treatment of superior mesenteric artery syndrome are alleviation of obstructive symptoms and reversal of any precipitating factors. As noted above, weight loss is commonly associated. However, if surgery has altered the anatomy, the likelihood that conservative therapy will be successful is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42649027\">",
"    <span class=\"h2\">",
"     Gastrointestinal decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have a nasogastric tube placed and correction of electrolyte abnormalities. A nasogastric tube decompresses the dilated stomach and proximal duodenum, improving patient comfort and aiding in monitoring fluid losses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/16/9480?source=see_link\">",
"     \"Nasogastric and nasoenteric tubes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=see_link&amp;anchor=H14#H14\">",
"     \"Small bowel obstruction: Causes and management\", section on 'Nonoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42649053\">",
"    <span class=\"h2\">",
"     Correction of electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are acutely ill may have electrolyte abnormalities, which should be monitored and corrected aggressively. Emesis can lead to hypovolemia, hypokalemia, and metabolic alkalosis. Fluid and electrolyte repletion should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following relief of duodenal obstruction, refeeding syndrome can contribute to electrolyte abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42649034\">",
"    <span class=\"h2\">",
"     Nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major component of therapy is nutritional support. Psychiatric evaluation may be needed to help manage an eating disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutritional support is usually required, at least in the initial stages until patients are able (and willing) to increase oral intake. Enteral nutrition is preferred and often administered through a nasojejunal feeding tube placed distal to the obstruction.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    may be necessary if enteral feeding is not an option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/42\">",
"     42",
"    </a>",
"    ]. Once significant weight gain is noted, the diet may be advanced slowly.",
"   </p>",
"   <p>",
"    In adults who have a brief history of symptoms and in children who tend to present acutely, conservative management with nutritional support has good success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/14,43\">",
"     14,43",
"    </a>",
"    ]. The adult patient with more chronic symptoms is less likely to benefit from nutritional support alone. For these patients, correction of electrolytes and decompression with a short course of nutrition should be followed soon by surgical management, if symptoms are not relieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645160\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several surgical options for the treatment of superior mesenteric artery syndrome if conservative nutritional therapy fails to resolve the condition. These include Strong&rsquo;s procedure (",
"    <a class=\"graphic graphic_figure graphicRef74196 \" href=\"mobipreview.htm?25/12/25807\">",
"     figure 2",
"    </a>",
"    ), gastrojejunostomy, and duodenojejunostomy with or without division or resection of the fourth part of the duodenum.",
"   </p>",
"   <p>",
"    Prior to surgery, the patient&rsquo;s nutritional status should be re-evaluated to ensure adequacy of wound healing. A multidisciplinary approach including dieticians and psychiatry consultation should be used to ensure the patient&rsquo;s well-being before and after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645232\">",
"    <span class=\"h1\">",
"     OPEN SURGERY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strong&rsquo;s procedure &ndash; Strong&rsquo;s procedure mobilizes the duodenum by dividing the ligament of Treitz [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/44\">",
"       44",
"      </a>",
"      ]. Once the duodenal-jejunal junction has been fully mobilized, the duodenum is positioned to the right of the superior mesenteric artery so it does not lie within the space between the aorta and the superior mesenteric artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/45\">",
"       45",
"      </a>",
"      ]. The integrity of the bowel is maintained; however, the short branches of the inferior pancreaticoduodenal artery may limit the ability of the duodenum to fall away from the aorta.",
"     </li>",
"     <li>",
"      Gastrojejunostomy &ndash; Gastrojejunostomy is performed by bringing a loop of jejunum up to the stomach and performing a side-to-side anastomosis (",
"      <a class=\"graphic graphic_figure graphicRef53190 \" href=\"mobipreview.htm?37/7/38015\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Duodenojejunostomy &ndash; With duodenojejunostomy the duodenum can be left intact or divided and the proximal jejunum brought through the right mesocolon to perform a side-to-side duodenojejunostomy (",
"      <a class=\"graphic graphic_figure graphicRef66614 \" href=\"mobipreview.htm?17/9/17555\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645240\">",
"    <span class=\"h2\">",
"     Laparoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful laparoscopic duodenojejunal bypass has also been described. Although experience is limited, it offers a less invasive surgical option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Advanced laparoscopic techniques have been described for the Strong procedures and duodenojejunostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/47,49\">",
"     47,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645255\">",
"    <span class=\"h2\">",
"     Follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast studies are performed at one to two weeks postoperatively to demonstrate patency of the repair and normal emptying of the duodenum. Patients are followed for resolution of their preoperative symptoms and weight gain is monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42645248\">",
"    <span class=\"h2\">",
"     Outcomes and complications of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few reports of long-term outcomes in patients with superior mesenteric artery syndrome who have undergone surgery. One of the largest series included 16 patients who were followed seven years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/4\">",
"     4",
"    </a>",
"    ]. Weight loss had been corrected in all patients. However, symptoms were essentially unchanged with the exception of vomiting, which was significantly decreased. In another series of eight patients, symptoms were improved; however, significant weight gain was not seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each of the surgical approaches has advantages and disadvantages. Strong&rsquo;s procedure maintains the integrity of the bowel; however, failure occurs in up to one fourth of patients. Gastrojejunostomy decompresses the stomach but the failure to relieve the duodenal obstruction may result in recurrent symptoms requiring a second procedure and the unrelieved obstruction may result in blind loop syndromes or peptic ulceration. Duodenojejunostomy is generally accepted as having superior results to both Strong&rsquo;s procedure and gastroenterostomy. Duodenojejunostomy with division of the fourth part of the duodenum establishes bowel continuity and minimizes the issues associated with a blind loop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors resect the third portion of the duodenum altogether. The rationale for this practice is the feeling that superior mesenteric artery syndrome is a variant of a motility disorder rather than a true mechanical obstruction. However, there is little evidence, either pathological or physiologic to support this notion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37799/abstract/9\">",
"     9",
"    </a>",
"    ]. Following relief of obstruction, normal duodenal motility can be demonstrated with gastrointestinal contrast studies. (See",
"    <a class=\"local\" href=\"#H42645255\">",
"     'Follow up'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior mesenteric artery (SMA) syndrome is a clinical entity characterized by a decreased acuity of the angle between the aorta and superior mesenteric artery due to the loss of mesenteric fat between the SMA and aorta resulting in compression of the third portion of the duodenum. Patients present with symptoms consistent with a proximal small bowel obstruction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There remains some controversy surrounding the diagnosis (and even the existence) of superior mesenteric artery syndrome, since symptoms do not always correlate well with radiologic findings, and do not always improve following treatment. Furthermore, the diagnosis may be confused with other anatomic or motility-related causes of duodenal obstruction. The most common risk factor is significant weight loss as a consequence of medical disorders, psychological disorders or surgery. Anatomic abnormalities (congenital or acquired) can also contribute. (See",
"      <a class=\"local\" href=\"#H42646666\">",
"       'Patients at risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can be challenging because superior mesenteric artery syndrome is uncommon and symptoms can be nonspecific. Thus, a high index of suspicion is required in the appropriate clinical setting. Patients should undergo judicious testing for other disorders that can cause similar clinical features. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established in patients with clinical features that suggest duodenal obstruction and noninvasive imaging that demonstrates an abnormal angle between the aorta and the superior mesenteric artery. Conventional arteriography may be needed for those patients in whom the diagnosis remains unclear. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may initially require gastric decompression, fluid resuscitation and correction of electrolyte abnormalities. We suggest reversal of weight loss as initial therapy for superior mesenteric artery syndrome (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This generally requires enteral nutritional support but some patients may require parenteral nutrition. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Conservative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with superior mesenteric artery syndrome whose condition is not improved with conservative management, several surgical options are available including mobilization of the ligament of Treitz, gastrojejunostomy and duodenojejunostomy. Of these, duodenojejunostomy may provide the best results. (See",
"      <a class=\"local\" href=\"#H42645160\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/1\">",
"      DORPH MH. The cast syndrome; review of the literature and report of a case. N Engl J Med 1950; 243:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/2\">",
"      Wilkie, DP. Chronic duodenal ileus. Br J Surg 1921; 9:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/3\">",
"      Cohen LB, Field SP, Sachar DB. The superior mesenteric artery syndrome. The disease that isn't, or is it? J Clin Gastroenterol 1985; 7:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/4\">",
"      Ylinen P, Kinnunen J, H&ouml;ckerstedt K. Superior mesenteric artery syndrome. A follow-up study of 16 operated patients. J Clin Gastroenterol 1989; 11:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/5\">",
"      Hines JR, Gore RM, Ballantyne GH. Superior mesenteric artery syndrome. Diagnostic criteria and therapeutic approaches. Am J Surg 1984; 148:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/6\">",
"      DERRICK JR, FADHLI HA. SURGICAL ANATOMY OF THE SUPERIOR MESENTERIC ARTERY. Am Surg 1965; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/7\">",
"      Ozkurt H, Cenker MM, Bas N, et al. Measurement of the distance and angle between the aorta and superior mesenteric artery: normal values in different BMI categories. Surg Radiol Anat 2007; 29:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/8\">",
"      Sapkas G, O'Brien JP. Vascular compression of the duodenum (cast syndrome) associated with the treatment of spinal deformities. A report of six cases. Arch Orthop Trauma Surg 1981; 98:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/9\">",
"      Merrett ND, Wilson RB, Cosman P, Biankin AV. Superior mesenteric artery syndrome: diagnosis and treatment strategies. J Gastrointest Surg 2009; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/10\">",
"      Agarwal T, Rockall TA, Wright AR, Gould SW. Superior mesenteric artery syndrome in a patient with HIV. J R Soc Med 2003; 96:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/11\">",
"      St&uuml;mpfle R, Wright AR, Walsh J. Superior mesenteric artery syndrome in an HIV positive patient. Sex Transm Infect 2003; 79:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/12\">",
"      Di Lecce F, Paini PB, Pagliari C, et al. [Superior mesenteric venous thrombosis. Report of 2 cases and review of the literature]. Chir Ital 2003; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/13\">",
"      Smith BM, Zyromski NJ, Purtill MA. Superior mesenteric artery syndrome: an underrecognized entity in the trauma population. J Trauma 2008; 64:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/14\">",
"      Reckler JM, Bruck HM, Munster AM, et al. Superior mesenteric artery syndrome as a consequence of burn injury. J Trauma 1972; 12:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/15\">",
"      Goitein D, Gagn&eacute; DJ, Papasavas PK, et al. Superior mesenteric artery syndrome after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/16\">",
"      Clapp B, Applebaum B. Superior mesenteric artery syndrome after Roux-en-y gastric bypass. JSLS 2010; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/17\">",
"      Baker MT, Lara MD, Kothari SN. Superior mesenteric artery syndrome after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2006; 2:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/18\">",
"      Schroeppel TJ, Chilcote WS, Lara MD, Kothari SN. Superior mesenteric artery syndrome after laparoscopic Roux-en-Y gastric bypass. Surgery 2005; 137:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/19\">",
"      Laffont I, Bensmail D, Rech C, et al. Late superior mesenteric artery syndrome in paraplegia: case report and review. Spinal Cord 2002; 40:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/20\">",
"      Barnes JB, Lee M. Superior mesenteric artery syndrome in an intravenous drug abuser after rapid weight loss. South Med J 1996; 89:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/21\">",
"      Pentlow BD, Dent RG. Acute vascular compression of the duodenum in anorexia nervosa. Br J Surg 1981; 68:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/22\">",
"      Gwee K, Teh A, Huang C. Acute superior mesenteric artery syndrome and pancreatitis in anorexia nervosa. Australas Psychiatry 2010; 18:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/23\">",
"      Zeraska M, Tomaszewicz-Libudzic C, Jagielska G, Komender J. [Surgical complications occurring during hospitalization of patients with anorexia nervosa--literature review and a discussion of three cases]. Psychiatr Pol 2002; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/24\">",
"      Adson DE, Mitchell JE, Trenkner SW. The superior mesenteric artery syndrome and acute gastric dilatation in eating disorders: a report of two cases and a review of the literature. Int J Eat Disord 1997; 21:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/25\">",
"      Zadegan F, Lenoir T, Drain O, et al. [Superior mesenteric artery syndrome following correction of spinal deformity: case report and review of the literature]. Rev Chir Orthop Reparatrice Appar Mot 2007; 93:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/26\">",
"      Schwartz A. Scoliosis, superior mesenteric artery syndrome, and adolescents. Orthop Nurs 2007; 26:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/27\">",
"      Vitale MG, Higgs GB, Liebling MS, et al. Superior mesenteric artery syndrome after segmental instrumentation: a biomechanical analysis. Am J Orthop (Belle Mead NJ) 1999; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/28\">",
"      Zhu ZZ, Qiu Y. Superior mesenteric artery syndrome following scoliosis surgery: its risk indicators and treatment strategy. World J Gastroenterol 2005; 11:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/29\">",
"      Crowther MA, Webb PJ, Eyre-Brook IA. Superior mesenteric artery syndrome following surgery for scoliosis. Spine (Phila Pa 1976) 2002; 27:E528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/30\">",
"      Cho KR, Jo WM. Superior mesenteric artery syndrome after esophagectomy with cervical esophagogastrostomy. Ann Thorac Surg 2006; 82:e37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/31\">",
"      Iwaoka Y, Yamada M, Takehira Y, et al. Superior mesenteric artery syndrome in identical twin brothers. Intern Med 2001; 40:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/32\">",
"      Caspi B, Deutsch H, Grunshpan M, et al. Prenatal manifestation of superior mesenteric artery syndrome. Prenat Diagn 2003; 23:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/33\">",
"      Tseng CK, Su WB, Lai HC, et al. Superior mesenteric artery syndrome caused by celiac axis compression syndrome: a case report and review of the literature. Eur J Gastroenterol Hepatol 2008; 20:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/34\">",
"      Lim JE, Duke GL, Eachempati SR. Superior mesenteric artery syndrome presenting with acute massive gastric dilatation, gastric wall pneumatosis, and portal venous gas. Surgery 2003; 134:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/35\">",
"      Fuhrman MA, Felig DM, Tanchel ME. Superior mesenteric artery syndrome with obstructing duodenal bezoar. Gastrointest Endosc 2003; 57:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/36\">",
"      Anderson FH. Megaduodenum. A case report and literature review. Am J Gastroenterol 1974; 62:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/37\">",
"      Neri S, Signorelli SS, Mondati E, et al. Ultrasound imaging in diagnosis of superior mesenteric artery syndrome. J Intern Med 2005; 257:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/38\">",
"      Unal B, Akta A, Kemal G, et al. Superior mesenteric artery syndrome: CT and ultrasonography findings. Diagn Interv Radiol 2005; 11:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/39\">",
"      Lippl F, Hannig C, Weiss W, et al. Superior mesenteric artery syndrome: diagnosis and treatment from the gastroenterologist's view. J Gastroenterol 2002; 37:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/40\">",
"      Santer R, Young C, Rossi T, Riddlesberger MM. Computed tomography in superior mesenteric artery syndrome. Pediatr Radiol 1991; 21:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/41\">",
"      Applegate GR, Cohen AJ. Dynamic CT in superior mesenteric artery syndrome. J Comput Assist Tomogr 1988; 12:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/42\">",
"      Munns SW, Morrissy RT, Golladay ES, McKenzie CN. Hyperalimentation for superior mesenteric-artery (cast) syndrome following correction of spinal deformity. J Bone Joint Surg Am 1984; 66:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/43\">",
"      Biank V, Werlin S. Superior mesenteric artery syndrome in children: a 20-year experience. J Pediatr Gastroenterol Nutr 2006; 42:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/44\">",
"      STRONG EK. Mechanics of arteriomesentric duodenal obstruction and direct surgical attack upon etiology. Ann Surg 1958; 148:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/45\">",
"      Wilson-Storey D, MacKinlay GA. The superior mesenteric artery syndrome. J R Coll Surg Edinb 1986; 31:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/46\">",
"      Gersin KS, Heniford BT. Laparoscopic duodenojejunostomy for treatment of superior mesenteric artery syndrome. JSLS 1998; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/47\">",
"      Richardson WS, Surowiec WJ. Laparoscopic repair of superior mesenteric artery syndrome. Am J Surg 2001; 181:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/48\">",
"      Bermas H, Fenoglio ME. Laparoscopic management of superior mesenteric artery syndrome. JSLS 2003; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37799/abstract/49\">",
"      Massoud WZ. Laparoscopic management of superior mesenteric artery syndrome. Int Surg 1995; 80:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8179 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37799=[""].join("\n");
var outline_f36_58_37799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42646666\">",
"      PATIENTS AT RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42647470\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42647589\">",
"      Plain abdominal films",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42647596\">",
"      Oral contrast studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42647642\">",
"      Diagnostic imaging criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONSERVATIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42649027\">",
"      Gastrointestinal decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42649053\">",
"      Correction of electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42649034\">",
"      Nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42645160\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42645232\">",
"      OPEN SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42645240\">",
"      Laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42645255\">",
"      Follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42645248\">",
"      Outcomes and complications of surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8179|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/21/29021\" title=\"diagnostic image 1\">",
"      Lateral arteriogram SMA syn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/37/30302\" title=\"diagnostic image 2A\">",
"      UGI-SMA syndrome I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/8/7296\" title=\"diagnostic image 2B\">",
"      UGI-SMA syndrome II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/25/12693\" title=\"diagnostic image 3\">",
"      SMA syndrome ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/31/16894\" title=\"diagnostic image 4A\">",
"      CT scan SMA syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/47/13042\" title=\"diagnostic image 4B\">",
"      Abdominal CT scan showing superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8179|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/39/2678\" title=\"figure 1\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/12/25807\" title=\"figure 2\">",
"      Strong procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/7/38015\" title=\"figure 3\">",
"      Gastrojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/9/17555\" title=\"figure 4\">",
"      Duodenojejunostomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/43/27316?source=related_link\">",
"      Celiac artery compression syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_58_37800="Fertility awareness-based methods of pregnancy prevention";
var content_f36_58_37800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fertility awareness-based methods of pregnancy prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Victoria Jennings, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37800/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/58/37800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility awareness-based (FAB) methods for preventing pregnancy are based upon the physiological changes during the menstrual cycle and the functional lifespan of sperm and ova. FAB methods rely on the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The periodicity of fertility and infertility",
"     </li>",
"     <li>",
"      A single ovulation each cycle",
"     </li>",
"     <li>",
"      The limited duration of viability of the ovum, which can only be fertilized 12 to 24 hours after release",
"     </li>",
"     <li>",
"      The limited duration of viability of sperm (three to five days in cervical mucus and the upper genital tract)",
"     </li>",
"     <li>",
"      A woman's ability to monitor cycle length",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cycle-related symptoms and signs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These methods, also called \"natural family planning,\" involve identifying the fertile days of the menstrual cycle using a combination of cycle length and physical manifestations of ovulation (change in cervical secretions, basal body temperature) and then avoiding sexual intercourse or using barrier methods on those days. These methods can also be used in reverse to improve the chance of conception by couples attempting to conceive.",
"   </p>",
"   <p>",
"    Surveys and behavioral research worldwide indicate that women who choose FAB methods do so because of their concerns about side effects and health consequences of other contraceptive methods. Religious constraints appear to play a small part in their method choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/2\">",
"     2",
"    </a>",
"    ]. Although many women have concerns about non-FAB methods of pregnancy prevention, most of these women have not embraced FAB methods. Only about 1 percent of women in the United States use FAB contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/3\">",
"     3",
"    </a>",
"    ] and 3.6 percent use it worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/1\">",
"     1",
"    </a>",
"    ]. Possible explanations include lack of information, inconvenience, and concerns about efficacy (high typical user failure rate).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lack of information",
"      </strong>",
"      &mdash; The lack of readily available patient information on FAB methods is likely related to at least three factors: (1) the absence of a profitable product to advertise and sell, (2) provider concern that these methods are not as effective as other choices, and (3) the amount of time needed to counsel patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. Studies including both physicians and nurse midwives have shown that relatively few providers routinely include information about FAB methods in their family planning discussions with patients. As an example, a survey of approximately 500 physicians in the United States found that one-third did not mention FAB methods to their patients at all, while 40 percent mentioned them only to selected women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/5\">",
"       5",
"      </a>",
"      ]. When asked by a patient for information about a FAB method, most physicians described either calendar rhythm or basal body temperature, which are among the least effective FAB methods (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Historical methods'",
"      </a>",
"      below). In another study, nurse-midwives offered little information about FAB methods based on their perception that these methods were not effective or were inappropriate for their patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Convenience",
"      </strong>",
"      &mdash; FAB methods can be labor-intensive for the clinician because of the time required for choosing the most appropriate method for an individual woman and for teaching her the method. These methods also require ongoing effort on the woman's part and impact spontaneity in sexual relations. Development of FAB methods that are relatively easy to incorporate into regular clinical services and use may increase interest and availability.",
"     </li>",
"     <li>",
"      <strong>",
"       Efficacy",
"      </strong>",
"      &mdash; Typical user failure rates are several-fold higher than correct use failure rates (",
"      <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"       table 1",
"      </a>",
"      ), similar to other user dependent methods of pregnancy prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFYING THE FERTILE PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, FAB methods of pregnancy prevention are based on identifying the fertile days of the menstrual cycle and then avoiding sexual intercourse or using barrier methods on those days. Studies using sensitive pregnancy tests have established that a woman is fertile from five days before ovulation to the 24 hours after ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/7\">",
"     7",
"    </a>",
"    ]. The probability of pregnancy from unprotected intercourse during this period is (",
"    <a class=\"graphic graphic_figure graphicRef74756 \" href=\"mobipreview.htm?21/19/21821\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4 percent five days before ovulation",
"     </li>",
"     <li>",
"      25 to 28 percent two days preceding ovulation",
"     </li>",
"     <li>",
"      8 to 10 percent during the 24 hours after ovulation",
"     </li>",
"     <li>",
"      0 percent for the remainder of the cycle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These probabilities are related to the limited viable lifespan of the sperm inside the woman's reproductive tract (not more than five days) and to the even more limited viable lifespan of the ovum following ovulation (less than 24 hours). As a result, the fertile window is no more than six days per cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Correctly timing ovulation is critical for determining when the six-day fertile window is likely to occur. Ovulation can be predicted using a combination of cycle length and physical manifestations of ovulation (change in cervical secretions, basal body temperature).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Determining ovulation by cycle length",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 95 percent of menstrual cycles, ovulation occurs in the four days before or after the mid-point of the cycle, and in approximately 30 percent of cycles, ovulation occurs at the exact mid-point of the cycle (eg, day 14 in a 28 day cycle, day 15 in a 30 day cycle) (",
"    <a class=\"graphic graphic_figure graphicRef66024 \" href=\"mobipreview.htm?30/34/31277\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A computer model that applied the probability of ovulation on any given day and the probability of conception before and after ovulation calculated that the fertile period in women with menstrual cycles of 26 to 32 days was on days 8 through 19 (cycle day 1 is the first day of the menstrual period) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Determining ovulation by cervical secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abundant, clear, wet, stretchy cervical secretions occur immediately before, during, and immediately after ovulation, thus, the day of ovulation can be predicted by observing changes in vaginal discharge that occur over a typical 28-day menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/9\">",
"     9",
"    </a>",
"    ]. The sequence of change is: menses; followed by no secretions for three to four days; followed by scant, cloudy, sticky secretions for three to five days; followed by abundant, clear, wet, stretchy secretions for the three to four days immediately before, during, and immediately after ovulation; and finally, no secretions for 11 to 14 days, at which time the next menstrual period begins. The duration of these phases varies by cycle length and in individual women.",
"   </p>",
"   <p>",
"    The characteristics of cervical secretions during the menstrual cycle are affected by serum estradiol and progesterone concentrations. Before ovulation, estradiol produced by the developing follicle stimulates the production of cervical secretions that facilitate passage of sperm through the cervix and lead to functional maturation of sperm (capacitation) so that fertilization of the ovum is possible. Following ovulation, progesterone produced by the corpus luteum causes an abrupt change in secretions, which then inhibit sperm migration and capacitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determining ovulation by basal body temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a normal menstrual cycle, basal body temperature (BBT) is approximately 0.5 degrees Fahrenheit (0.3 degrees Celsius) higher in the luteal phase than in the follicular phase. The temperature rise begins one or two days after the surge in luteinizing hormone and the rise in progesterone concentrations, and persists for at least 10 days. Temperature elevation identifies ovulation retrospectively and thus signifies the end, rather than the onset, of the fertile period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR FERTILITY-AWARENESS BASED PREGNANCY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential candidates for FAB methods are women who desire an alternative to other (barrier, intrauterine, hormonal or surgical) methods of family planning for health or personal reasons, are able to comply with FAB method requirements, and will abstain from sexual intercourse (or use barrier methods) on fertile days. The most appropriate candidates for FAB methods are women with regular cycles.",
"   </p>",
"   <p>",
"    Characteristics of FAB methods that are perceived by some to be advantageous may be perceived by others to be disadvantageous. For example, the importance of the male partner's participation (eg, abstaining or using condoms during fertile days) and the need to be aware of one's body through daily assessment of cervical secretions (and possibly body temperature) are viewed as positives by some women, while others find these issues problematic and inconvenient.",
"   </p>",
"   <p>",
"    The effectiveness of a contraceptive method for preventing unplanned pregnancy is critically important. In general, methods that require no routine action on the part of the user are highly effective and demonstrate little difference between correct and typical-use failure rates, whereas methods that require routine action on the part of the user show more disparity between these rates. FAB methods, like all methods that require daily user action, have higher correct use than typical use efficacy, and this disparity is greater for more complex methods than for simpler ones (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. This highlights the need for screening and counseling women who elect to use these methods and choosing methods to which they can adhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following physiological circumstances represent relative contraindications to use of FAB because of the difficulty in predicting ovulation during these periods.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent menarche, childbirth, or discontinuation of some hormonal contraceptives",
"     </li>",
"     <li>",
"      Approaching menopause",
"     </li>",
"     <li>",
"      Currently breastfeeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For example, just after menarche cycles are irregular so the Standard Days Method would be difficult to use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Similarly, breastfeeding women may have continuous cervical secretions that do not indicate ovulation and would find methods that require observation of cervical secretions difficult to use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/16\">",
"     16",
"    </a>",
"    ]. However, instructions have been developed for using the cervical mucus or ovulation method and the symptothermal method under these \"special circumstances.\" (See The Art of Natural Family Planning Postpartum Guide and Premenopause Guide available from the Couple to Couple League at",
"    <a class=\"external\" href=\"file://www.ccli.org/\">",
"     www.ccli.org",
"    </a>",
"    ). A pilot study reported a fertility-awareness-based bridge for postpartum women to start with their first postpartum menses and until they are eligible to use the Standard Days method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FERTILITY-AWARENESS BASED METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal FAB method is easy to use and minimizes the number of days that sexual intercourse must be avoided or practiced with a barrier contraceptive. Method requirements are also important since women with certain characteristics should avoid certain FAB methods.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Standard Days Method is not appropriate for women with cycles frequently shorter than 26 days or longer than 32 days.",
"     </li>",
"     <li>",
"      The ovulation, TwoDay, and symptothermal methods are not appropriate for women unable to interpret their fertility signs correctly and women with persistent reproductive tract infections that affect their ability to interpret cervical secretions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17529990\">",
"    <span class=\"h2\">",
"     Calendar methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Standard Days Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Standard Days Method (SDM) determines fertile days using two sets of probabilities: the probability of pregnancy with respect to ovulation and the probability of correctly timing ovulation with respect to the mid-point of the cycle.",
"   </p>",
"   <p>",
"    It is the easiest FAB method to teach and use and has the fewest days requiring abstinence or barrier contraception. The only instruction is to avoid unprotected intercourse from day 8 through day 19 of the cycle (12 days); the user may have unprotected intercourse on all other days.",
"   </p>",
"   <p>",
"    The SDM is appropriate for women whose menstrual cycles are usually between 26 and 32 days (approximately 78 percent of cycles are within this range) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, women with polycystic ovary syndrome, adolescents, breastfeeding women with amenorrhea, women who are recently postpartum, and women in the menopausal transition often are not good candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial in which nearly 500 women were taught this method and followed prospectively for up to 13 cycles reported a pregnancy rate of &lt;5 per 100 women per year with correct use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/12\">",
"     12",
"    </a>",
"    ]. The typical user pregnancy rate of the SDM was 12 per 100 women per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in SDM counseling is assessing whether the method is appropriate for the individual woman. While it is not necessary for her to know her exact cycle length, a \"yes\" response to two questions: \"Do your periods usually come about one month apart?\" and \"Do your periods usually come when you expect them?\" is sufficient for this assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The figure provides guidance for initiating SDM use (",
"    <a class=\"graphic graphic_table graphicRef53914 \" href=\"mobipreview.htm?30/53/31579\">",
"     table 2",
"    </a>",
"    ). Women who know when their last period started can begin using the SDM immediately; those who do not know should wait until their next period begins. Women who were recently pregnant, breastfeeding, or using hormonal contraception should be asked about their recent and past menstrual history to determine whether SDM is appropriate for them and when to start it.",
"   </p>",
"   <p>",
"    Women should monitor their cycle length while using SDM since some women have less regular cycles than they initially believed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/2\">",
"     2",
"    </a>",
"    ]. The SDM is less effective in women with frequent cycles outside the 26- to 32-day range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, women who have more than one cycle longer than 32 days or shorter than 26 days in a 12-month period should be encouraged to use another method.",
"   </p>",
"   <p>",
"    Most women can learn to use the SDM in about 20 minutes. We suggest women use a visual tool such as CycleBeads&reg;, a string of 32 color-coded beads (",
"    <a class=\"graphic graphic_figure graphicRef53853 \" href=\"mobipreview.htm?32/14/32998\">",
"     figure 3",
"    </a>",
"    ), or an iCycleBeads software application (",
"    <a class=\"graphic graphic_figure graphicRef83607 \" href=\"mobipreview.htm?28/38/29281\">",
"     figure 4",
"    </a>",
"    ), in order to track their cycle days, visually indicate their fertile days (days 8 to 19), and monitor cycle lengths to be sure they are between 26 and 32 days. Several studies have confirmed that CycleBeads is a critical component of teaching and correctly using the SDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/20\">",
"     20",
"    </a>",
"    ]. CycleBeads is available through some family planning clinics and retailers; CycleBeads, as well as the iCycleBeads Online web service and iCycleBeads software applications (for iPhone and Android devices), are available through www.cyclebeads.com.",
"   </p>",
"   <p>",
"    To use CycleBeads or the iCycleBeads software applications, a woman must track the first day of her period each cycle. The tools include a marker which helps her track her cycle day and whether she is fertile that day. Users are counseled to avoid unprotected intercourse when the rubber ring is on a white bead, representing fertile days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cervical mucus or ovulation method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical mucus or ovulation method requires women to evaluate their cervical secretions several times each day to decide whether the day is a potentially fertile day, thus it takes more time to teach and learn than other methods. Unprotected intercourse is avoided on potentially fertile days plus some additional days as specified by method rules (see below). As a result, cervical mucus method users need to avoid unprotected intercourse for about 14 to 17 days each cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/21\">",
"     21",
"    </a>",
"    ]. Examples of cervical mucus methods are the Billings Ovulation, Creighton Model, and TwoDay methods. Cervical mucus can also be assessed using a variety of devices. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Methods using mini-microscopes, computers, and other devices (eg, Marquette)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17530359\">",
"    <span class=\"h3\">",
"     Billings and Creighton methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Billings Ovulation method is the oldest method of observing cervical secretions for fertility awareness. A variant on the Billings Ovulation method, the Creighton Model, requires that the woman score the secretions according to a multi-characteristic scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies of the efficacy of cervical mucus or ovulation methods have been conducted. A large well-designed study conducted by the World Health Organization in the early 1980s included 725 women from five countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/23\">",
"     23",
"    </a>",
"    ]. The correct use failure rate was 3 per 100 women per year, and the typical user failure rate was 23 per 100 women per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/24\">",
"     24",
"    </a>",
"    ]. The large difference between correct and typical use reflects the complexity of learning and using the method correctly, as well as the choice of some couples to have unprotected intercourse on fertile days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women require several instructional sessions to recognize the pattern of secretions in a typical menstrual cycle. In these sessions, they learn to observe, record, and interpret their cervical secretions, paying particular attention to the color, elasticity, abundance, and viscosity.",
"   </p>",
"   <p>",
"    Learning to observe secretions at the vulva and evaluate them is critical for using this method. Women are encouraged to make these observations several times each day, preferably prior to each urination. Techniques include touching the vulva with the fingers or toilet paper to collect secretions and assess their characteristics, noting secretions on underwear, and simply \"feeling\" wetness at the vulva.",
"   </p>",
"   <p>",
"    Various approaches to recording observations have been developed to help women become familiar with their fertile patterns over time. Commonly, women use a chart on which they mark days of menses, days with secretions (including characteristics of secretions), and days when pregnancy is likely. Cervical mucus method users are counseled to avoid unprotected intercourse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During menses (because of the possibility that menstrual bleeding could obscure the presence of secretions, particularly in short cycles)",
"     </li>",
"     <li>",
"      On preovulatory days following days with intercourse (even if there are no secretions present, because of the possible confusion with semen)",
"     </li>",
"     <li>",
"      On all days with wet, slippery, transparent, or stretchy secretions consistent with ovulation",
"     </li>",
"     <li>",
"      Until four days past the last day with wet secretions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these rules, the user avoids unprotected intercourse for approximately 14 to 17 days of each cycle.",
"   </p>",
"   <p>",
"    An example of patient record is shown in the figure (",
"    <a class=\"graphic graphic_table graphicRef64637 \" href=\"mobipreview.htm?16/38/17006\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     TwoDay method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TwoDay Method is based on assessment of cervical secretions, similar to the method described above, but it is less cumbersome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/25\">",
"     25",
"    </a>",
"    ]. The principal difference is that, for the TwoDay Method, the mere presence or absence of cervical secretions is considered sufficient to determine the fertile period. TwoDay method users are counseled to avoid unprotected intercourse on all days that they note the presence of secretions and on the first day following a day with secretions. The presence of secretions conforms sufficiently to the actual fertile window so that further evaluation of the secretions' characteristics is not necessary.",
"   </p>",
"   <p>",
"    An analysis of almost 4000 cycles in women using the TwoDay Method found that the mean length of the identified fertile period was 13 days, thus users needed to avoid unprotected intercourse for about 13 days of each cycle (range 10 to 14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, multi-site efficacy study of the TwoDay Method followed 450 women for up to 13 cycles of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/13\">",
"     13",
"    </a>",
"    ]. The first-year correct use pregnancy rate was 3.5 per 100 women per year, and the typical use pregnancy rate was &lt;14 per 100 women per year. The lower typical use failure rate of the TwoDay Method compared to the cervical mucus or ovulation method is probably due to its simplicity. Women may find it easier to learn and use, and thus are more likely to use it correctly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women can learn to use the TwoDay Method in a single counseling session when they present for family planning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/26\">",
"     26",
"    </a>",
"    ]. They learn what to expect in terms of presence and absence of secretions in a typical menstrual cycle: no secretions immediately following menses, secretions (of various types) beginning a few days after menses and continuing for several days, and absence of secretions again until after the next menses.",
"   </p>",
"   <p>",
"    TwoDay Method users monitor the presence or absence of secretions and then ask themselves two questions: \"Did I have any secretions today?\" and \"Did I have any secretions yesterday?\" (",
"    <a class=\"graphic graphic_algorithm graphicRef51450 \" href=\"mobipreview.htm?5/52/5965\">",
"     algorithm 1",
"    </a>",
"    ). If any secretions were noted today or yesterday, today is a potentially fertile day and she should avoid unprotected intercourse. If she did not notice any secretions today or yesterday (ie, two consecutive days with no secretions), her probability of conceiving today is very low and unprotected intercourse is permitted.",
"   </p>",
"   <p>",
"    Learning to recognize whether or not they have secretions at the vulva is critical for TwoDay Method use. Women are encouraged to make these observations two times each day: once during the afternoon and once before going to bed at night. (If they have intercourse at times other than at night or early in the morning, they should adjust the times of observation accordingly to avoid confusing the presence of semen with secretions). As with the Billings or Creighton methods, users of the TwoDay Method note secretions on toilet paper or underwear, or by the feel at the vulva. Women usually use a chart to record the presence or absence of secretions and menses and thus identify their fertile days (",
"    <a class=\"graphic graphic_figure graphicRef60185 \" href=\"mobipreview.htm?37/52/38735\">",
"     figure 5",
"    </a>",
"    ). Women can learn to use the TwoDay Method anytime during a cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17530223\">",
"    <span class=\"h2\">",
"     Multimodal methods",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Symptothermal method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptothermal method is based on changes in cervical secretions and basal body temperature produced by hormonal changes during the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/27\">",
"     27",
"    </a>",
"    ]. The presence of wet, slippery, transparent, or stretchy cervical secretions is the primary indicator of the beginning of the fertile phase of the cycle, and BBT elevation is the primary indicator of the end of the fertile phase.",
"   </p>",
"   <p>",
"    The symptothermal method requires women to observe and evaluate their cervical secretions several times each day, take their temperature with a BBT thermometer (a thermometer calibrated to be easy to read in the temperature range of interest) each morning before rising, and record and interpret these findings to determine whether the day is a fertile day. Some symptothermal method users also check the position and feel of the cervix. Users of the symptothermal method need to abstain or avoid unprotected intercourse for approximately 12 to 17 days each cycle.",
"   </p>",
"   <p>",
"    This method can be used by women with short, long, or irregular cycles. It is cumbersome and has no significant advantages over other methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy studies indicate that this method has a correct use first year pregnancy rate of 2 per 100 women per year and a typical user pregnancy rate between 13 and 20 per 100 women per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/10,28,29\">",
"     10,28,29",
"    </a>",
"    ]. The wide range in failure rates reflects differences in study designs. The large difference between correct and typical use failure rates probably reflects the complexity of learning and using the method correctly and issues around avoiding unprotected intercourse on fertile days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women require several instructional sessions to use the symptothermal method. They learn to observe, record, and interpret their cervical secretions, as well as to take their temperature using a BBT thermometer. They record their temperatures on a chart and attempt to identify the temperature rise associated with ovulation. Three higher temperatures following at least six days of lower temperature indicate that ovulation has occurred.",
"   </p>",
"   <p>",
"    Symptothermal method users are counseled to avoid unprotected intercourse on potentially fertile days, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All days with secretions",
"     </li>",
"     <li>",
"      All preovulatory days following days with intercourse (even if there are no secretions present because of the possible confusion with semen)",
"     </li>",
"     <li>",
"      Until three days of higher temperature have followed at least six days of lower temperatures, or the fourth day after the last day with wet secretions, whichever happens later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Learning to observe and evaluate their secretions, and to take and observe their BBT, is critical for symptothermal method use. Women are encouraged to observe secretions before each urination and to take their temperature each day before rising. They record their observations of menses, secretions (and their characteristics), and temperature on a chart (",
"    <a class=\"graphic graphic_figure graphicRef50946 \" href=\"mobipreview.htm?10/19/10554\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Methods using mini-microscopes, computers, and other devices (eg, Marquette)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several devices that can help women identify their fertile days. These include mini microscopes that allow women to observe ferning of saliva or of cervical mucus (eg, PG53, PC2000, Maybe Baby), and handheld computers that measure cycle length and correlate the day of the cycle with BBT (eg, Babycomp, Ladycomp, Bioself 2000, Cyclotest 2 Plus). Research to evaluate the effectiveness of some of these devices to prevent pregnancy suggests that mini microscope-type devices would have high failure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/30\">",
"     30",
"    </a>",
"    ]. Studies of mini microscopes have not found them to be effective in helping women prevent pregnancy. Studies that have assessed the contraceptive efficacy of computing devices are inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In one study, Persona, which measures urinary hormone metabolites to identify the fertile days, had a failure rate of 6 percent with correct use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/34\">",
"     34",
"    </a>",
"    ]. The cost of these devices can be prohibitive for many women.",
"   </p>",
"   <p>",
"    Studies of women using the Clearblue Easy Fertility Monitor indicate that the device provides accurate information about the fertile window, particularly when used with a calendar-based formula to double check the beginning and end of the fertile phase.&nbsp;This approach is referred to as the Marquette Model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EFFICACY AND LIMITATIONS OF DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of various FAB and other contraceptive methods is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 1",
"    </a>",
"    ). There are no high-quality randomized trials comparing efficacy of different FAB methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most early efficacy studies of FAB methods (specifically of the cervical mucus or ovulation method and the symptothermal method) enrolled women only after they had completed a learning phase, typically consisting of three cycles of use, while others enrolled women from the day they started using the methods. Since failure rates are highest during the early cycles of use, when patients are enrolled can be an important factor in study outcome. Subsequent studies of the Standard Days Method and the TwoDay Method enrolled women as soon as they started using the methods. Results of these studies showed that over 20 percent of couples had intercourse during their fertile days when they first learned to use a method, but that this percent dropped sharply during the first three months and continued to decline during the first year of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/38\">",
"     38",
"    </a>",
"    ], which partially explains the difference in reported failure rates for FAB methods. The fact that the Standard Days Method and the TwoDay Method are easier to use than the ovulation and symptothermal methods also may result in regular use, and thus greater effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of direct harm from use of FAB methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the harm from unintended pregnancies needs to be considered when evaluating any contraceptive method. Women with certain medical conditions should be advised that sole use of barrier methods for contraception and behavior-based methods of contraception may not be the most appropriate choice because of their relatively higher typical-use rates of failure.",
"   </p>",
"   <p>",
"    Because unintended pregnancies among couples who use FAB methods usually result from having intercourse at the beginning or end of the fertile time, concerns have been raised about the risk of birth defects or poor pregnancy outcomes due to aged ovum or sperm. There is no evidence to support these concerns. Fertilization of aging gametes (ie, age from ejaculation or ovulation) is not associated with major birth defects or Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/41\">",
"     41",
"    </a>",
"    ]. A prospective study that evaluated rates of spontaneous abortion, low birth weight, or preterm birth among women who had an unintended pregnancy while using a FAB method versus women who had intended pregnancies reported no significant differences in these outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/40\">",
"     40",
"    </a>",
"    ]. An exception is that, in one prospective study, women with a history of spontaneous abortion had a greater chance of having another spontaneous abortion when conception occurred very early or late in the fertile time (23 percent versus 10 to 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HISTORICAL METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Calendar rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early decades of the 20th century, it was known that women were more likely to become pregnant at midcycle and that the luteal phase was of a more fixed length than the follicular phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/42\">",
"     42",
"    </a>",
"    ]. The calendar rhythm method was developed based on this information.",
"   </p>",
"   <p>",
"    This method requires that, prior to using the method, the woman determine the length of her last six cycles and then subtract 18 from the number of days in her shortest cycle and 11 from the number of days in her longest cycle. This determines her fertile period, when unprotected intercourse should be avoided. As an example, if her shortest cycle is 26 days and her longest cycle is 34 days, then her fertile period is from day 8 to 23.",
"   </p>",
"   <p>",
"    While undoubtedly serving to prevent many unplanned pregnancies, calendar rhythm resulted in high failure rates because it required the user to maintain records of cycle length prior to and during method use, involved arithmetical calculations each cycle, had no eligibility criteria, and had poorly-defined parameters. No well-designed efficacy trials of the calendar rhythm method have been conducted, and generally it is not offered in clinical services today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Basal body temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;By mid-century, the importance of the biphasic basal body temperature (BBT) pattern in determining ovulation was recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37800/abstract/43\">",
"     43",
"    </a>",
"    ]. Since BBT elevation identifies the end of the fertile period rather than the onset, users of this method have to avoid unprotected intercourse from the beginning of the cycle until at least three days of elevated temperature have occurred (ie, for well over one-half of the month). Thus, it is not a popular choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ON-LINE RESOURCES FOR FERTILITY AWARENESS-BASED METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17961847\">",
"    <span class=\"h2\">",
"     Standard Days and TwoDay methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the Standard Days and TwoDay methods is available from the Georgetown University Institute for Reproductive Health at",
"    <a class=\"external\" href=\"file://www.irh.org/\">",
"     www.irh.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17961854\">",
"    <span class=\"h2\">",
"     Cervical mucus or ovulation methods (Billings, Creighton)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information on the Billings ovulation method is available from the World Organisation of the Ovulation Method Billings at",
"      <a class=\"external\" href=\"file://www.woomb.org/\">",
"       www.woomb.org",
"      </a>",
"      and Billings Life at",
"      <a class=\"external\" href=\"file://www.thebillingsovulationmethod.org/#\">",
"       www.the billingsovulationmethod.org",
"      </a>",
"     </li>",
"     <li>",
"      Information on the Creighton Model is available from the CREIGHTON MODEL FertilityCare&trade; System at",
"      <a class=\"external\" href=\"file://www.creightonmodel.com/\">",
"       www.creightonmodel.com",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17961868\">",
"    <span class=\"h2\">",
"     Symptothermal method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the symptothermal method is available from the Fertility United Kingdom at",
"    <a class=\"external\" href=\"file://www.fertilityuk.org/\">",
"     www.fertilityuk.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17961875\">",
"    <span class=\"h2\">",
"     Marquette Model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the Marquette Model is available from Marquette University at",
"    <a class=\"external\" href=\"file://nfp.marquette.edu/\">",
"     file://nfp.marquette.edu",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fertility awareness-based (FAB) methods of pregnancy prevention involve identifying the fertile days of the menstrual cycle by assessing cycle length",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      observable signs of ovulation (cervical secretions, basal body temperature), and then avoiding unprotected sexual intercourse on those days. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Identifying the fertile period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should choose a FAB method based on their preferences regarding the procedures involved in using each method and the number of days per cycle during which the user needs to avoid unprotected intercourse, while accounting for the specific constraints of the method. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fertility-Awareness based methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Standard Days Method (avoid unprotected intercourse from day 8 through 19) is only appropriate for women with regular cycles of 26 to 32 days. It is the easiest FAB method to teach and use, and many women learn to use it without counseling through information available at www.cyclebeads.com. The user abstains or uses a barrier method for 12 days, which is fewer days than for the ovulation or symptothermal methods. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Standard Days Method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TwoDay Method users are counseled to avoid unprotected intercourse on days when they note cervical secretions and on the day after the day with cervical secretions. It is the easiest cervical secretion method to learn and perform. The TwoDay method can be used by women with short, long, or irregular cycles. Users of the TwoDay Method abstain or use a barrier method for approximately 13 days each cycle. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'TwoDay method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cervical mucus or ovulation method requires women to observe and evaluate their cervical secretions several times each day and avoid unprotected intercourse based on their findings. This method may be used by women with short, long, or irregular cycles, but is time consuming to teach, learn, and practice. Based on the rules of the cervical mucus or ovulation method, the user avoids unprotected intercourse for about 14 to 17 days each cycle. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cervical mucus or ovulation method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptothermal method requires women to observe and evaluate their cervical secretions several times each day and take their temperature with a basal body temperature (BBT) thermometer each morning before rising. This method can be used by women with short, long, or irregular cycles. Users of the symptothermal method avoid unprotected intercourse for approximately 12 to 17 days each cycle. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Symptothermal method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that use of FAB methods increase the risk of adverse pregnancy outcomes if an unintended pregnancy occurs. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/1\">",
"      Freundl G, Sivin I, Bat&aacute;r I. State-of-the-art of non-hormonal methods of contraception: IV. Natural family planning. Eur J Contracept Reprod Health Care 2010; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/2\">",
"      Gribble JN, Lundgren RI, Velasquez C, Anastasi EE. Being strategic about contraceptive introduction: the experience of the Standard Days Method. Contraception 2008; 77:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/3\">",
"      Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/4\">",
"      Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/5\">",
"      Stanford JB, Thurman PB, Lemaire JC. Physicians' knowledge and practices regarding natural family planning. Obstet Gynecol 1999; 94:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/6\">",
"      Fehring RJ, Hanson L, Stanford JB. Nurse-midwives' knowledge and promotion of lactational amenorrhea and other natural family-planning methods for child spacing. J Midwifery Womens Health 2001; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/7\">",
"      Wilcox AJ, Weinberg CR, Baird DD. Post-ovulatory ageing of the human oocyte and embryo failure. Hum Reprod 1998; 13:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/8\">",
"      Ar&eacute;valo M, Sinai I, Jennings V. A fixed formula to define the fertile window of the menstrual cycle as the basis of a simple method of natural family planning. Contraception 1999; 60:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/9\">",
"      Alliende ME, Cabez&oacute;n C, Figueroa H, Kottmann C. Cervicovaginal fluid changes to detect ovulation accurately. Am J Obstet Gynecol 2005; 193:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/10\">",
"      Guida M, Tommaselli GA, Pellicano M, et al. An overview on the effectiveness of natural family planning. Gynecol Endocrinol 1997; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/11\">",
"      Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence. Fam Plann Perspect 1990; 22:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/12\">",
"      Ar&eacute;valo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception 2002; 65:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/13\">",
"      Ar&eacute;valo M, Jennings V, Nikula M, Sinai I. Efficacy of the new TwoDay Method of family planning. Fertil Steril 2004; 82:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/14\">",
"      World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care 1986; 7:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/15\">",
"      O'Connor KA, Holman DJ, Wood JW. Menstrual cycle variability and the perimenopause. Am J Hum Biol 2001; 13:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/16\">",
"      Ar&eacute;valo M, Jennings V, Sinai I. Application of simple fertility awareness-based methods of family planning to breastfeeding women. Fertil Steril 2003; 80:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/17\">",
"      Sinai I, Cachan J. A Bridge for postpartum women to Standard Days Method&reg;: II. Efficacy study. Contraception 2012; 86:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/18\">",
"      Ferrell RJ, Simon JA, Pincus SM, et al. The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported. Fertil Steril 2006; 86:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/19\">",
"      Sinai I, Jennings V, Ar&eacute;valo M. The importance of screening and monitoring: the Standard Days Method and cycle regularity. Contraception 2004; 69:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/20\">",
"      Gribble JN. The standard days method of family planning: a response to Cairo. Int Fam Plan Perspect 2003; 29:188.",
"     </a>",
"    </li>",
"    <li>",
"     World Organization Observation Billings Method. The Billings Ovulation Method: Observations, Charting and Rules page. www.woomb.org/bom/rules/#observations. (Accessed on July 05, 2005).",
"    </li>",
"    <li>",
"     Hilgers, TW. The Scientific Foundations of the Ovulation Method. Pope John Paul IV Institute, Omaha 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/23\">",
"      A prospective multicentre trial of the ovulation method of natural family planning. I. The teaching phase. Fertil Steril 1981; 36:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/24\">",
"      Trussell J, Grummer-Strawn L. Further analysis of contraceptive failure of the ovulation method. Am J Obstet Gynecol 1991; 165:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/25\">",
"      Sinai I, Jennings V, Ar&eacute;valo M. The TwoDay Algorithm: a new algorithm to identify the fertile time of the menstrual cycle. Contraception 1999; 60:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/26\">",
"      Jennings V, Sinai I, Sacieta L, Lundgren R. TwoDay Method: a quick-start approach. Contraception 2011; 84:144.",
"     </a>",
"    </li>",
"    <li>",
"     Clubb, E, Knight, J. Fertility: Fertility Awareness and Natural Family Planning. David &amp; Charles, Devon, UK 1996.",
"    </li>",
"    <li>",
"     Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive Technology, 19th ed, Ardent Media, Inc, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/29\">",
"      Frank-Herrmann P, Heil J, Gnoth C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod 2007; 22:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/30\">",
"      Freundl G, Godehardt E, Kern PA, et al. Estimated maximum failure rates of cycle monitors using daily conception probabilities in the menstrual cycle. Hum Reprod 2003; 18:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/31\">",
"      Fehring RJ, Raviele K, Schneider M. A comparison of the fertile phase as determined by the Clearplan Easy Fertility Monitor and self-assessment of cervical mucus. Contraception 2004; 69:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/32\">",
"      Bonnar J, Freundl G, Kirkman R. Personal hormone monitoring for contraception. Br J Fam Plann 2000; 26:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/33\">",
"      Guida M, Bramante S, Acunzo G, et al. [Diagnosis of fertility with a personal hormonal evaluation test]. Minerva Ginecol 2003; 55:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/34\">",
"      Bonnar J, Flynn A, Freundl G, et al. Personal hormone monitoring for contraception. Br J Fam Plann 1999; 24:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/35\">",
"      Fehring RJ, Schneider M, Raviele K. Pilot evaluation of an internet-based natural family planning education and service program. J Obstet Gynecol Neonatal Nurs 2011; 40:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/36\">",
"      Fehring R, Schneider M, Raviele K, et al. Randomized comparison of two internet-supported fertility awareness based methods of family planning. Contraception :in press.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/37\">",
"      Grimes DA, Gallo MF, Halpern K, et al. Fertility awareness-based methods for contraception. Cochrane Database Syst Rev 2012; :CD004860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/38\">",
"      Sinai I, Ar&eacute;valo M. It's all in the timing: coital frequency and fertility awareness-based methods of family planning. J Biosoc Sci 2006; 38:763.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Johns Hopkins Bloomberg School of Public Health. USAID. Family Planning: A Global Handbook for Providers, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/40\">",
"      Gray RH, Simpson JL, Kambic RT, et al. Timing of conception and the risk of spontaneous abortion among pregnancies occurring during the use of natural family planning. Am J Obstet Gynecol 1995; 172:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/41\">",
"      Simpson JL, Gray R, Perez A, et al. Fertilisation involving ageing gametes, major birth defects, and Down's syndrome. Lancet 2002; 359:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/42\">",
"      Klaus H. Natural family planning: a review. Obstet Gynecol Surv 1982; 37:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37800/abstract/43\">",
"      Marshall J. A field trial of the basal-body-temperature method of regulating births. Lancet 1968; 2:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5456 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-93F80B87AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37800=[""].join("\n");
var outline_f36_58_37800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFYING THE FERTILE PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Determining ovulation by cycle length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Determining ovulation by cervical secretions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determining ovulation by basal body temperature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CANDIDATES FOR FERTILITY-AWARENESS BASED PREGNANCY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FERTILITY-AWARENESS BASED METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17529990\">",
"      Calendar methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Standard Days Method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cervical mucus or ovulation method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17530359\">",
"      - Billings and Creighton methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - TwoDay method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17530223\">",
"      Multimodal methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Symptothermal method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Methods using mini-microscopes, computers, and other devices (eg, Marquette)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EFFICACY AND LIMITATIONS OF DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HISTORICAL METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Calendar rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Basal body temperature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ON-LINE RESOURCES FOR FERTILITY AWARENESS-BASED METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17961847\">",
"      Standard Days and TwoDay methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17961854\">",
"      Cervical mucus or ovulation methods (Billings, Creighton)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17961868\">",
"      Symptothermal method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17961875\">",
"      Marquette Model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5456|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?5/52/5965\" title=\"algorithm 1\">",
"      Two day method algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5456|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/19/21821\" title=\"figure 1\">",
"      Probability of pregnancy by day of intercourse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/34/31277\" title=\"figure 2\">",
"      Probability of ovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/14/32998\" title=\"figure 3\">",
"      Cyclebeads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/38/29281\" title=\"figure 4\">",
"      iCycleBeads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/52/38735\" title=\"figure 5\">",
"      Two day method chart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/19/10554\" title=\"figure 6\">",
"      Symptothermal chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13197\" title=\"table 1\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/53/31579\" title=\"table 2\">",
"      Standard days method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/38/17006\" title=\"table 3\">",
"      Cyclic changes cx secretions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_58_37801="Mitral annular calcification";
var content_f36_58_37801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitral annular calcification",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Rosario V Freeman, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/58/37801/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/58/37801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular calcification (MAC) is a common degenerative process involving the fibrous annulus of the mitral valve. It is generally an incidental finding associated with aging although it is occasionally associated with significant mitral regurgitation and can rarely cause symptomatic mitral stenosis. In addition, MAC is associated with atrial fibrillation, conduction system disease, atherosclerotic disease and adverse cardiovascular events, including stroke and mortality.",
"   </p>",
"   <p>",
"    The diagnosis, clinical significance, and associated cardiovascular risk of MAC and management of MAC related disorders are discussed here.",
"   </p>",
"   <p>",
"    Echocardiography of the mitral valve, mitral valve disease and conduction system disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitral valve annulus is the C-shaped segment of the fibrous skeleton at the base of the left ventricle at its junction with the left atrium. The leaflets of the mitral valve are attached to and suspended from the mitral annulus which provides structural support to the valve apparatus along the medial, posterior, and lateral aspects of the valve. Anteriorly, the mid-section of the anterior mitral leaflet is in fibrous continuity (via the intervalvular fibrosa) with the posterior aortic root without intervening annular tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitral annular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular calcification (MAC) develops from progressive calcium deposition along and beneath the mitral valve annulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/1\">",
"     1",
"    </a>",
"    ]. MAC generally follows the C-shape of the mitral annulus so the base of the anterior mitral leaflet is generally (but not always [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/2\">",
"     2",
"    </a>",
"    ]) spared. MAC is most commonly identified by echocardiography as an echodense shelf-like structure involving the mitral valve annulus with associated acoustic shadowing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70235 \" href=\"mobipreview.htm?12/36/12864\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80124 \" href=\"mobipreview.htm?11/26/11680\">",
"     image 2",
"    </a>",
"    ). The calcification frequently has an irregular, lumpy appearance. Although mitral valve leaflets and chordae tendinae are generally not involved, calcification may progressively accumulate in the subvalvular region beneath the posterior leaflet with encroachment on the leaflet. Usual sparing of the leaflet commissures and anterior leaflet distinguishes MAC from rheumatic mitral involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Caseous calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caseous calcification of the mitral annulus is a rare (less than one percent) variant of MAC which appears as a smooth, round periannular mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. On echocardiography, caseous calcification is less echodense than typical MAC, a central echolucent zone is present, and acoustic shadowing is generally absent. The caseous contents of the mass have a putty-like consistency with microscopic features consistent with liquefaction necrosis with amorphous eosinophilic acellular material surrounded by macrophages and lymphocytes and multiple small calcifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited longitudinal observations indicate that caseous calcification may be a dynamic condition. Caseous calcification may spontaneously resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/5\">",
"     5",
"    </a>",
"    ] or convert to typical MAC, and typical MAC may rarely convert to caseous calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caseous calcification is a benign condition and should not be misdiagnosed as a myocardial abscess, tumor, or thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tricuspid annular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcified lesions similar to MAC occur along the tricuspid annulus (tricuspid annular calcification or TAC). Although data are scant, TAC is much less common than MAC, and does not progress to hemodynamically significant obstruction of right ventricular inflow. TAC has been reported in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/6\">",
"     6",
"    </a>",
"    ] and in patients with pulmonic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/7\">",
"     7",
"    </a>",
"    ]. Like MAC, a variant of TAC with caseous calcification has been reported (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86968 \" href=\"mobipreview.htm?20/42/21154\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;In various study populations with mean ages of approximately 50 to 60 years, the prevalence of MAC was 3 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. The prevalence of MAC increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/8,9,13-15\">",
"     8,9,13-15",
"    </a>",
"    ]. In the multiethnic Northern Manhattan study cohort of 1955 subjects 40 years of age or older (mean age 68 years) without prior myocardial infarction or ischemic stroke, mitral annular calcification was identified by two-dimensional echocardiography in 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In two population-based studies with mean ages of 70 and 76 years, the prevalence of MAC was 14 percent (by M-mode echocardiography) and 42 percent (by two-dimensional echocardiography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data on whether the prevalence of MAC is higher in women than men, as observed in some populations such as the Framingham Heart Study and the MESA population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/12,13,15,16\">",
"     12,13,15,16",
"    </a>",
"    ], or is similar in women and men as noted in the ARIC study and the Cardiovascular Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/9,10,14\">",
"     9,10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progressive, calcific process associated with MAC appears to be accelerated and more prominent in those with altered mineral metabolism, such as those with chronic renal disease. Prevalence of valvular calcification (aortic and mitral annular) is high in patients with end-stage renal disease (ESRD): about 35 to 50 percent in patients with ESRD with mean age of 50 to 60 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. MAC is more prevalent among those dialyzed for a longer period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/17\">",
"     17",
"    </a>",
"    ] and is associated with coronary artery disease, atherosclerotic vascular disease, and mortality among those with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an analysis of data from the Multi-Ethnic Study of Atherosclerosis (MESA) on 6785 participants, MAC was present in 8 percent of the participants with estimated glomerular filtration rate (eGFR) &ge;60",
"    <span class=\"nowrap\">",
"     mL/min/1.72",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    (mean age 62 years) and in 20 percent of participants with eGFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.72",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    (mean age 70 years). In adjusted analyses, eGFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.72",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    was associated with MAC among subjects with diabetes, but not among those without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 3929 subjects (mean age 74&plusmn;5 years, 60 percent women) in the Cardiovascular Health Study, moderate kidney disease (eGFR",
"    <em>",
"     &lt;",
"    </em>",
"    45",
"    <span class=\"nowrap\">",
"     mL/min/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was significantly associated with MAC (OR 1.54), but not with aortic annular calcification or aortic valve sclerosis. Cystatin C levels (another marker of renal insufficiency) were also associated with MAC (OR 1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    One small study found a similar prevalence of MAC and aortic valve calcification in age-matched patients with and without ESRD although the size of MAC was larger among those with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/6\">",
"     6",
"    </a>",
"    ]. Basal mitral leaflet calcification and papillary muscle calcification were much more common in patients with ESRD. Tricuspid annular calcification (TAC) and calcification of the intervalvular fibrosa (adjacent to the anterior mitral leaflet) were noted only in patients ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data on the pathophysiology of MAC are very limited, an atherosclerotic process similar to that observed for calcific aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/22\">",
"     22",
"    </a>",
"    ] has been proposed since atherosclerosis and MAC are strongly associated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Clinical associations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It has been suggested that development of MAC, like calcific aortic valve disease and atherosclerosis, may be initiated by endothelial disruption at foci of increased mechanical stress, such as at the junction between the mitral valve annulus and ventricular myocardium. Focal accumulation of oxidized lipids may serve as a nidus for chronic inflammatory cell infiltrates including T lymphocytes and macrophages, as well as activated mast cells that promote extracellular matrix remodeling, as seen in calcific aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Focal calcific deposits in regions of microinjury and lipoprotein accumulation may then coalesce over time into the dense, fibrotic, rigid band macroscopically evident as MAC.",
"   </p>",
"   <p>",
"    Development of MAC may also reflect systemic disorders of tissue mineralization associated with kidney disease or atherosclerosis. Among patients with end-stage renal disease, presence of MAC was associated with an elevated calcium-phosphate product in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/17,19,27\">",
"     17,19,27",
"    </a>",
"    ]. In individuals with coronary heart disease without severe kidney disease, presence of MAC is inversely associated with serum fetuin A, a multifunctional glycoprotein that inhibits dystrophic calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/28\">",
"     28",
"    </a>",
"    ]. Serum fetuin A is also inversely associated with valvular calcification (including MAC) in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early development of MAC (in adolescence or young adulthood) has been reported in patients with genetic abnormalities of the fibrous skeleton (eg, Marfan syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/30\">",
"     30",
"    </a>",
"    ]), and with chronic inflammatory disorders (eg, systemic lupus erythematosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/31\">",
"     31",
"    </a>",
"    ]). Hypertension is a risk factor for MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/10\">",
"     10",
"    </a>",
"    ], perhaps due to increased mechanical stress on the mitral valve apparatus or due to its association with atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcification of the mitral annulus is readily recognizable by echocardiography, appearing as a bright echodense region adjacent to the posterior atrioventricular groove (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70235 \" href=\"mobipreview.htm?12/36/12864\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80124 \" href=\"mobipreview.htm?11/26/11680\">",
"     image 2",
"    </a>",
"    ). MAC is most commonly an incidental finding on echocardiographic imaging, and is characteristically identified on parasternal and apical views of the left heart with acoustic shadowing of structures beyond (posterior to) the calcification.",
"   </p>",
"   <p>",
"    Severity of MAC is typically reported qualitatively, with calcification of less than one-third of the annulus graded as \"mild\", and greater than two-thirds graded as \"severe.\" The thickness of the calcific band can also be measured via M-mode imaging from the parasternal long-axis view. MAC thickness correlates with cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Mortality and cardiovascular risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Spectral Doppler interrogation of the mitral valve from the apical views of the heart provides hemodynamic data on functional restriction of left ventricular inflow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86969 \" href=\"mobipreview.htm?37/0/37890\">",
"     image 4",
"    </a>",
"    ). Color Doppler imaging can aid in evaluating the mechanism and severity of concurrent mitral regurgitation, although transthoracic images of mitral regurgitation jets in the left atrium are frequently suboptimal due to acoustic shadowing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86970 \" href=\"mobipreview.htm?34/21/35154\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a retrospective echocardiography study of 24,380 echocardiographic examinations, age, left ventricular hypertrophy, mitral regurgitation, tricuspid regurgitation, aortic stenosis, left atrial enlargement, and reversed",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio were independently associated with MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of MAC on echocardiographic interpretation is discussed below (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Impact on echocardiography'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the chief imaging modality for identification and characterization of MAC, although MAC may also be identified by other modalities such as chest radiography, fluoroscopy, and computed tomography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. MAC is less prominent on magnetic resonance imaging since calcium is hypointense compared to myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is generally an incidental finding associated with aging although it is occasionally associated with significant mitral regurgitation and can rarely cause symptomatic mitral stenosis.",
"   </p>",
"   <p>",
"    The presence of MAC is also associated with increased risk of atrial fibrillation, conduction system disease, atherosclerotic disease, and adverse cardiovascular events, including stroke and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mitral valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usually asymptomatic and clinically silent, MAC generally has little or no impact on left ventricular inflow or mitral valve function. However, extensive calcification can occasionally cause functional mitral stenosis (MS) or mitral regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mitral stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC occasionally causes calcific MS with hemodynamically significant obstruction to left ventricular inflow with impairment of normal diastolic annular dilation which may be accompanied by restriction of mitral valve leaflet motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/35\">",
"     35",
"    </a>",
"    ]. Limited data are available on the prevalence of calcific MS. In a study of 100 patients &ge;62 years old with MAC, a mean mitral gradient of at least 5 mmHg and a calculated mitral valve area (MVA, by pressure half-time method) of &le;1.8 cm2 was found in 6 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/36\">",
"     36",
"    </a>",
"    ]. Similarly, a calculated MVA (by pressure half-time method) &lt;2cm2 was found in 8 percent of patients in a smaller study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these data based on MVA by pressure half-time may underestimate the true prevalence of MAC-associated MS since MVA by pressure half-time method may overestimate MVA in patients with MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/38\">",
"     38",
"    </a>",
"    ]. In a study comparing MVA by 3D echocardiography with MVA by pressure half-time and MVA by continuity equation in patients with calcific MS, MVA by pressure half-time was significantly larger than MVA by continuity equation, while MVA by 3D echocardiography was similar to MVA by continuity equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/38\">",
"     38",
"    </a>",
"    ]. In calcific MS, the stenotic orifice is tubular since obstruction extends from the mitral annulus to the leaflet tips while in rheumatic MS the orifice is funnel shaped since obstruction is present at the leaflet tips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC and mitral regurgitation (MR) are frequently associated. Since each of these two lesions is relatively common, they would be expected to coincide in many patients even without a causal relationship. However, there is limited evidence that MAC is associated with an increased risk of MR and can cause or exacerbate MR in some cases. In a review of nearly 25,000 echocardiograms, MAC was present in 11.7 percent of patients with MR and in 4.3 percent without MR. In two small studies, MR was detected in 54 and 63 percent of patients with MAC and at least moderate MR was detected in 18 and 33 percent with MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. MAC may cause mitral regurgitation by preventing normal systolic annular contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/35\">",
"     35",
"    </a>",
"    ] and in some cases may also restrict leaflet mobility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Aortic valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the similarities in pathologic appearance and clinical associations between MAC and aortic sclerosis, it is not surprising that patients with MAC often have concurrent calcification of the aortic valve annulus, aortic valve leaflets, and aortic root [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/39\">",
"     39",
"    </a>",
"    ]. MAC is a risk factor for hemodynamic progression of calcific aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is associated with reduced early and late diastolic annular velocities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/40\">",
"     40",
"    </a>",
"    ]. Reduction in mitral annular motion in patients with MAC may be due to diastolic dysfunction associated with left ventricular hypertrophy, which is associated with MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Impact on tissue Doppler'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Conduction system disease and bradyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is associated with a high prevalence of conduction system disease (including atrioventricular block, bundle branch block and intraventricular conduction delay) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/34\">",
"     34",
"    </a>",
"    ]. An association between severity of MAC and risk of conduction system disease has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/41\">",
"     41",
"    </a>",
"    ]. MAC is also associated with an increased rate of symptomatic bradyarrhythmias (due to sinus arrest or conduction system disease) requiring permanent pacemaker implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between MAC and conduction disease may be partially due to direct extension of calcific deposits to the region of the AV node and His bundle. In a small study, conduction abnormalities (atrioventricular block), bundle branch block or intraventricular conduction delay were more common in patients with MAC near the conduction system (53 percent) than in those with MAC further from the conduction system (26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the prevalence of conduction disturbances even among those with MAC remote from the primary conduction system as well as the prevalence of remote conduction disease (eg, sinoatrial dysfunction) in patients with MAC suggests that diffuse degenerative conduction system disease is frequently associated with MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found an association between MAC and atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/12,44,45\">",
"     12,44,45",
"    </a>",
"    ]. A report from the Framingham Heart Study including 16 years of follow-up of 1126 subjects found that MAC was an independent predictor of incident atrial fibrillation (adjusted HR 1.6 95% CI 1.1-2.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/45\">",
"     45",
"    </a>",
"    ]. The association between MAC and incident atrial fibrillation was attenuated after adjustment for left atrial size, so the relationship between MAC and atrial fibrillation may be partially mediated through left atrial enlargement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is significantly associated with coronary artery disease as detected by radionuclide myocardial perfusion imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/46\">",
"     46",
"    </a>",
"    ], coronary computed tomography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/11,47\">",
"     11,47",
"    </a>",
"    ], or invasive coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. For example, in a population of 2,465 patients with mean age 69 years who underwent coronary angiography for suspected coronary artery disease, the presence of MAC was associated with increased prevalence of &gt;70 percent coronary artery stenosis (80 percent in those with MAC versus 69 percent in those without MAC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, significant three vessel disease was more common in patients with severe MAC (47 percent) and in those with mild to moderate MAC (35 percent) than in those with no MAC (30 percent).",
"   </p>",
"   <p>",
"    Similarly, in the MESA population of 6814 subjects undergoing coronary computed tomographic scans, coronary artery calcification was present in 3398 (50 percent of the study cohort). After taking into account demographics and other risk factors, the prevalence ratio of MAC in those with mild CAC (1 to 99) was 2.13 (95% CI 1.69-2.69) but increased to 7.57 (95% CI 5.95-9.62) for CAC &gt;400. This association weakened but persisted after adjustment for age, gender, and other traditional cardiovascular risk factors, suggesting that MAC presence is an indicator of atherosclerotic burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is associated with atherosclerosis of the aorta, independent of cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/10,51\">",
"     10,51",
"    </a>",
"    ]. MAC is also strongly associated with carotid artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mortality and cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC, similar to other forms of cardiac calcification (such as aortic valve sclerosis), is associated with adverse cardiovascular outcomes, including myocardial infarction, heart failure (HF), and death in various populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/9,12,15,16,53,54\">",
"     9,12,15,16,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 16 years of follow-up of 1197 subjects in the Framingham Heart Study, the presence of MAC was related to adverse outcomes. MAC was associated with an increased risk of incident cardiovascular disease (CVD, including myocardial infarction, coronary insufficiency, heart failure, and nonhemorrhagic stroke) (HR 1.5, 95% CI, 1.1-2.0), CVD death (HR 1.6, 95% CI 1.1-2.3) and all-cause death (HR 1.3, 95% CI 1.0-1.6), after multivariable adjustment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/47\">",
"       47",
"      </a>",
"      ]. The risks of incident CVD, CVD death, and all-cause death increased by approximately 10 percent for each one mm increase in MAC thickness.",
"     </li>",
"     <li>",
"      At mean 6.6 year follow-up of 3782 subjects in the Cardiovascular Health Study, MAC, aortic annular calcification and aortic sclerosis were each associated with increased risk of adverse outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/54\">",
"       54",
"      </a>",
"      ]. Of the three, MAC was most strongly associated with HF events (adjusted HR 1.7, 95% CI, 1.4-2.2). MAC was also associated with cardiovascular death (HR 1.3, 95% CI 1.1-1.6) and all-cause death (HR 1.8, 95% CI 1.3-2.5).",
"     </li>",
"     <li>",
"      At mean 4.8 year follow-up of 2409 African American participants in the ARIC cohort, MAC was independently associated with increased coronary heart disease events (hospitalized myocardial infarction, fatal coronary event) (adjusted HR 2.3, 95% CI 1.1-4.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Among 1955 subjects 40 years or older without prior myocardial infarction or ischemic stroke followed for mean duration of 7.4 years in the Northern Manhattan Study, MAC was associated with increased risk of MI (adjusted HR 1.75, 95% CI 1.13-2.69) and vascular death (adjusted HR 1.53, 95% CI 1.09-2.15), but not ischemic stroke after adjusting for cardiovascular risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/16\">",
"       16",
"      </a>",
"      ]. There was an association between MAC severity and these outcomes. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Belgrade Atrial Fibrillation Study of 1056 subjects with nonvalvular atrial fibrillation, subjects with MAC were more likely to be older, female, and to have a dilated left atrium, reduced left ventricular ejection fraction, permanent atrial fibrillation, hypertension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/12\">",
"       12",
"      </a>",
"      ]. MAC was associated with increased cardiovascular morbidity and mortality, and all-cause mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is associated with increased risk of ischemic stroke although studies are conflicting as to whether MAC is an independent predictor of stroke. MAC was identified as an independent risk factor for incident stroke in some large population studies (including the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/55\">",
"     55",
"    </a>",
"    ] and the Strong Heart Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/56\">",
"     56",
"    </a>",
"    ]) but not in others (such as the Cardiovascular Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/57\">",
"     57",
"    </a>",
"    ] and the Northern Manhattan Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/16\">",
"     16",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    For example, during an eight year follow-up of 1159 subjects from the Framingham cohort, MAC was associated with a relative risk of stroke of 2.10 (CI 1.24 -3.57) after multivariable adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, a study of the 5,888 subjects in the Cardiovascular Health Study cohort found that MAC was associated with increased risk of incident stroke but did not remain predictive of stroke after adjustment for risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subset of the Cardiovascular Health Study cohort, 2680 participants without history of stroke or transient ischemic attack underwent brain MRI and echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/58\">",
"     58",
"    </a>",
"    ]. The presence of annular or valvular calcification (MAC, aortic annular calcification, or aortic valve sclerosis) was significantly associated with higher prevalence of covert brain infarcts in models adjusting for cerebrovascular risk factors (risk ratio 1.24; 95% CI 1.05-1.47). Although the presence of MAC was associated with covert brain infarcts in minimally adjusted models, MAC was not associated with covert brain infarcts in the more fully adjusted model.",
"   </p>",
"   <p>",
"    Potential causes of stroke in patients with MAC include concurrent atrial fibrillation and vascular atherosclerotic disease, which are both associated with MAC. It is unclear whether or how often MAC itself may be a source of thromboembolism, although case reports have reported a rare finding of thrombus adherent to MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/59\">",
"     59",
"    </a>",
"    ]. Calcific emboli have occasionally been identified in patients with MAC; these may arise from concurrent vascular disease or possibly from MAC itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of endocarditis in patients with MAC is not known, case reports and series have described infective endocarditis involving the mitral valve in patients with MAC. Endocarditis lesions have included vegetations on the mitral valve leaflets, and less commonly vegetations adherent to MAC, as well as paravalvular abscesses in the region of MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/62\">",
"     62",
"    </a>",
"    ]. Limited observations suggest vegetations adherent to MAC are associated with greater comorbidity (eg, diabetes mellitus and cancer) and poor clinical outcome with high in hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/62\">",
"     62",
"    </a>",
"    ]. The presence of MAC may obscure echocardiographic detection of adjacent abscesses (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Detection of mitral valve abscess'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Limited data also suggest a poor prognosis among patients with MAC undergoing surgery for mitral regurgitation due to infective endocarditis. In one series of 24 patients with MAC and endocarditis (18 with acute and 6 with healed endocarditis) undergoing mitral surgery, in hospital mortality was 29 percent, with all early deaths in patients operated on during acute infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/63\">",
"     63",
"    </a>",
"    ]. Frequent comorbidities (eg, chronic kidney disease, cancer, coronary disease) likely contributed to the poor outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like atherosclerosis and calcific aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/22\">",
"     22",
"    </a>",
"    ], MAC is associated with systemic markers of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the observed association between MAC and systemic inflammatory markers may be largely due to shared risk factors. In a report from the Framingham Heart Study, valvular calcification including MAC was associated with elevated levels of inflammatory markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/64\">",
"     64",
"    </a>",
"    ]. The association was no longer significant after adjusting for accompanying cardiovascular disease risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     IMPACT ON ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of MAC can interfere with echocardiographic evaluation of mitral regurgitation, interpretation of tissue Doppler velocities, detection of mitral valve abscess, and evaluation of other adjacent structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Quantification of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acoustic shadowing from MAC frequently obscures Doppler echocardiographic quantification of concurrent mitral regurgitation. The impact of such shadowing may be reduced by acquiring multiple views of the valve on transthoracic echocardiography although in some cases transesophageal echocardiography (in which the left atrium is closer to the transducer and therefore not obscured by MAC) may be helpful to better visualize the extent of regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Impact on tissue Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that the presence of mitral annular calcification impairs the accuracy of the E to e' ratio estimation of pulmonary capillary wedge pressure. The e' velocity is usually reduced in patients with significant MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition the E may be increased if there is associated mitral regurgitation or mitral inflow gradient. Therefore, as noted in the 2009 American Society of Echocardiography recommendations for evaluation of diastolic function, the",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio is not accurate as an index of filling pressures in patients with heavy MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, although a preserved e' (&ge;7",
"    <span class=\"nowrap\">",
"     cm/s)",
"    </span>",
"    is generally helpful in distinguishing patients with constrictive pericarditis from those with restrictive cardiomyopathy, in patients with significant MAC and constrictive pericarditis, the e' may be &le;7",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Detection of mitral valve abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of MAC can interfere with echocardiographic identification of abscesses in the region of the calcified posterior mitral annulus. In a transesophageal echocardiography (TEE) study of 115 patients with definite infective endocarditis who underwent cardiac surgery, 38 percent had an abscess detected at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/67\">",
"     67",
"    </a>",
"    ]. TEE detected an abscess in 48% of those with an abscess. The majority (61 percent) of missed abscesses were localized to the posterior mitral annulus, which was frequently calcified. These data suggest that caution should be used in using TEE to exclude abscess in patients with infective endocarditis who have MAC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no established therapy for the prevention or treatment of MAC. However the presence of MAC is a sign of potential associated risk factors and cardiovascular conditions (as detailed above) that may require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Risk factor modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAC is strongly associated with atherosclerotic disease and adverse cardiovascular outcomes, as noted above. Thus, the presence of MAC should serve as a warning of potential concomitant coronary and atherosclerotic disease and as a reminder to address potential modifiable cardiovascular risk factors (such as hypertension and dyslipidemia). Cardiovascular risk factors should be evaluated and treated according to standard recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential impact of risk factor modification on MAC itself has not be evaluated. Studies on statin or ACE inhibitor therapy to prevent progression of calcific aortic valvular heart disease have been inconclusive and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Prevention of disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, MAC is associated with ischemic stroke; this association was independent of other cardiovascular risk factors in some studies but not others. Scant data are available to support specific antithrombotic recommendations in patients with MAC.",
"   </p>",
"   <p>",
"    Given the paucity of evidence for stroke or other thromboembolic prophylaxis for patients with MAC, we suggest that patients with MAC with ischemic stroke, TIA, or systemic embolic event be treated as other patients according to standard guidelines. This approach is largely consistent with the 2012 ACCP guideline recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H20#H20\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Antithrombotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, we disagree with one recommendation in the discussion of MAC in the 2012 ACCP guidelines. These guidelines suggest consideration of valve replacement for patients with MAC who have recurrent thromboembolic events despite antithrombotic therapy or evidence of multiple calcific emboli. Given the lack of evidence of efficacy of such an approach as well as the substantial risks of valve replacement, we recommend against mitral valve replacement as a treatment for thromboembolic events or calcific emboli in patients with MAC.",
"   </p>",
"   <p>",
"    For patients with MAC and atrial fibrillation, we suggest treatment according to standard recommendations for antithrombotic therapy for atrial fibrillation with risk-stratification based on the conventional risk factors assessed in the CHADS2 score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/38/1633?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Mitral valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic severe mitral stenosis or severe mitral regurgitation is generally an indication for mitral valve surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe MAC rarely causes symptomatic severe calcific mitral stenosis. In these patients, only surgical intervention can relieve the obstruction since percutaneous mitral valve balloon valvuloplasty (which treats commissural fusion in patients with rheumatic valve disease) is not effective to treat MAC.",
"   </p>",
"   <p>",
"    MAC is occasionally associated with significant mitral regurgitation which may be caused either by coexistent mitral valve disease (eg, myxomatous degeneration) or by MAC itself (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Mitral regurgitation'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    However, the presence of severe MAC complicates mitral valve surgery and is associated with high operative mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Surgical approaches for mitral disease associated with MAC include mitral valve repair following decalcification of the mitral annulus with annular reconstruction and valve replacement. Complications of mitral valve surgery include atrioventricular disruption, ventricular rupture, and left circumflex artery injury. It is necessary to avoid sewing a prosthetic mitral valve to a calcium bar to avoid paravalvular leak and valve dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/70\">",
"     70",
"    </a>",
"    ]. In surgical series at specialized centers employing a combination of mitral procedures, the operative mortality ranged from 9 to 14 percent with 5 year survival ranging from 79 to 73 percent. Thus, management of symptomatic mitral disease associated with MAC requires careful assessment of the potential risks and benefits of mitral valve surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endocarditis on or adjacent to MAC has been reported (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Endocarditis'",
"    </a>",
"    above), MAC with or without associated native mitral disease is NOT an indication for prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/58/37801/abstract/69\">",
"     69",
"    </a>",
"    ]. Prior endocarditis, a prosthetic mitral valve or a prosthetic mitral ring are among the indications for endocarditis prophylaxis under current guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Arrhythmia therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias associated with MAC such as atrial fibrillation and symptomatic bradyarrhythmias should be managed according to standard recommendations for these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H35\">",
"     'Antithrombotic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral annular calcification (MAC) is generally an incidental finding associated with aging, although it is occasionally associated with significant mitral regurgitation and can rarely cause symptomatic mitral stenosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mitral valve disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is associated with increased risk of coronary and vascular disease and adverse cardiovascular events, including stroke and mortality.",
"     </li>",
"     <li>",
"      Patients with MAC should undergo evaluation for potentially modifiable cardiovascular risk factors, such as hypertension and dyslipidemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical associations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Risk factor modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is particularly common in patients with end-stage renal disease and is associated with atherosclerotic disease and mortality in this population. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of MAC can obscure echocardiographic quantification of mitral regurgitation, identification of mitral valve abscess, and estimation of pulmonary capillary wedge pressure.",
"     </li>",
"     <li>",
"      MAC is associated with conduction system disease. Such disorders should be treated according to standard guidelines. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is associated with atrial fibrillation; data to support specific recommendations for patients with this combination of disorders are lacking. For patients with MAC with atrial fibrillation, we suggest following standard antithrombotic recommendations for atrial fibrillation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is associated with stroke, although data to support specific antithrombotic therapy in patients with MAC are lacking. For patients with MAC with stroke, TIA, or systemic embolic events, we suggest following standard antithrombotic recommendations for these conditions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When mitral valve surgery is indicated in patients with MAC, a careful assessment of potential risks and benefits should be performed since patients with MAC face high rates of operative morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Mitral valve surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/1\">",
"      Fulkerson PK, Beaver BM, Auseon JC, Graber HL. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med 1979; 66:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/2\">",
"      Roberts WC, Waller BF. Mitral valve \"anular\" calcium forming a complete circle or \"O\" configuration: clinical and necropsy observations. Am Heart J 1981; 101:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/3\">",
"      Harpaz D, Auerbach I, Vered Z, et al. Caseous calcification of the mitral annulus: a neglected, unrecognized diagnosis. J Am Soc Echocardiogr 2001; 14:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/4\">",
"      Deluca G, Correale M, Ieva R, et al. The incidence and clinical course of caseous calcification of the mitral annulus: a prospective echocardiographic study. J Am Soc Echocardiogr 2008; 21:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/5\">",
"      Gramenzi S, Mazzola AA, Tagliaferri B, et al. Caseous calcification of the mitral annulus: unusual case of spontaneous resolution. Echocardiography 2005; 22:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/6\">",
"      Bittrick J, D'Cruz IA, Wall BM, et al. Differences and similarities between patients with and without end-stage renal disease, with regard to location of intracardiac calcification. Echocardiography 2002; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/7\">",
"      Arnold JR, Ghahramani AR, Hernandez FA, Sommer LS. Calcification of annulus of tricuspid valve (observation in two patients with congenital pulmonary stenosis). Chest 1971; 60:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/8\">",
"      Movahed MR, Saito Y, Ahmadi-Kashani M, Ebrahimi R. Mitral annulus calcification is associated with valvular and cardiac structural abnormalities. Cardiovasc Ultrasound 2007; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/9\">",
"      Fox E, Harkins D, Taylor H, et al. Epidemiology of mitral annular calcification and its predictive value for coronary events in African Americans: the Jackson Cohort of the Atherosclerotic Risk in Communities Study. Am Heart J 2004; 148:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/10\">",
"      Allison MA, Cheung P, Criqui MH, et al. Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis. Circulation 2006; 113:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/11\">",
"      Hamirani YS, Nasir K, Blumenthal RS, et al. Relation of mitral annular calcium and coronary calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 2011; 107:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/12\">",
"      Potpara TS, Vasiljevic ZM, Vujisic-Tesic BD, et al. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study. Chest 2011; 140:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/13\">",
"      Savage DD, Garrison RJ, Castelli WP, et al. Prevalence of submitral (anular) calcium and its correlates in a general population-based sample (the Framingham Study). Am J Cardiol 1983; 51:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/14\">",
"      Barasch E, Gottdiener JS, Larsen EK, et al. Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS). Am Heart J 2006; 151:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/15\">",
"      Fox CS, Vasan RS, Parise H, et al. Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation 2003; 107:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/16\">",
"      Kohsaka S, Jin Z, Rundek T, et al. Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging 2008; 1:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/17\">",
"      Maher ER, Young G, Smyth-Walsh B, et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/18\">",
"      Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 95:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/19\">",
"      Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. Atherosclerosis 2007; 191:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/20\">",
"      Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/21\">",
"      Asselbergs FW, Mozaffarian D, Katz R, et al. Association of renal function with cardiac calcifications in older adults: the cardiovascular health study. Nephrol Dial Transplant 2009; 24:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/22\">",
"      Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/23\">",
"      Roberts WC. The senile cardiac calcification syndrome. Am J Cardiol 1986; 58:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/24\">",
"      Adler Y, Fink N, Spector D, et al. Mitral annulus calcification--a window to diffuse atherosclerosis of the vascular system. Atherosclerosis 2001; 155:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/25\">",
"      Helske S, Syv&auml;ranta S, Kupari M, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006; 27:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/26\">",
"      Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007; 18:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/27\">",
"      H&uuml;ting J. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 1994; 105:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/28\">",
"      Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/29\">",
"      Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/30\">",
"      Correia J, Rodrigues D, da Silva AM, et al. Massive calcification of the mitral valve annulus in an adolescent with Marfan syndrome. A case report. Rev Port Cardiol 2006; 25:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/31\">",
"      Molad Y, Levin-Iaina N, Vaturi M, et al. Heart valve calcification in young patients with systemic lupus erythematosus: a window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality. Atherosclerosis 2006; 185:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/32\">",
"      Di Bella G, Carerj S, And&ograve; G, et al. Cardiac imaging in the evaluation of mitral annulus caseous calcification. Int J Cardiol 2006; 113:E30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/33\">",
"      Gulati A, Chan C, Duncan A, et al. Multimodality cardiac imaging in the evaluation of mitral annular caseous calcification. Circulation 2011; 123:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/34\">",
"      D'Cruz IA, Cohen HC, Prabhu R, et al. Clinical manifestations of mitral annulus calcification, with emphasis on its echocardiographic features. Am Heart J 1977; 94:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/35\">",
"      Osterberger LE, Goldstein S, Khaja F, Lakier JB. Functional mitral stenosis in patients with massive mitral annular calcification. Circulation 1981; 64:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/36\">",
"      Aronow WS, Kronzon I. Correlation of prevalence and severity of mitral regurgitation and mitral stenosis determined by Doppler echocardiography with physical signs of mitral regurgitation and mitral stenosis in 100 patients aged 62 to 100 years with mitral anular calcium. Am J Cardiol 1987; 60:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/37\">",
"      Labovitz AJ, Nelson JG, Windhorst DM, et al. Frequency of mitral valve dysfunction from mitral anular calcium as detected by Doppler echocardiography. Am J Cardiol 1985; 55:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/38\">",
"      Chu JW, Levine RA, Chua S, et al. Assessing mitral valve area and orifice geometry in calcific mitral stenosis: a new solution by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2008; 21:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/39\">",
"      Jassal DS, Tam JW, Bhagirath KM, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Eur Heart J 2008; 29:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/40\">",
"      Soeki T, Fukuda N, Shinohara H, et al. Mitral inflow and mitral annular motion velocities in patients with mitral annular calcification: evaluation by pulsed Doppler echocardiography and pulsed Doppler tissue imaging. Eur J Echocardiogr 2002; 3:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/41\">",
"      Mellino M, Salcedo EE, Lever HM, et al. Echographic-quantified severity of mitral anulus calcification: prognostic correlation to related hemodynamic, valvular, rhythm, and conduction abnormalities. Am Heart J 1982; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/42\">",
"      Nair CK, Sketch MH, Desai R, et al. High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification. Am Heart J 1982; 103:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/43\">",
"      Takamoto T, Popp RL. Conduction disturbances related to the site and severity of mitral anular calcification: a 2-dimensional echocardiographic and electrocardiographic correlative study. Am J Cardiol 1983; 51:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/44\">",
"      Nair CK, Thomson W, Ryschon K, et al. Long-term follow-up of patients with echocardiographically detected mitral anular calcium and comparison with age- and sex-matched control subjects. Am J Cardiol 1989; 63:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/45\">",
"      Fox CS, Parise H, Vasan RS, et al. Mitral annular calcification is a predictor for incident atrial fibrillation. Atherosclerosis 2004; 173:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/46\">",
"      Jeon DS, Atar S, Brasch AV, et al. Association of mitral annulus calcification, aortic valve sclerosis and aortic root calcification with abnormal myocardial perfusion single photon emission tomography in subjects age &lt; or =65 years old. J Am Coll Cardiol 2001; 38:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/47\">",
"      Tenenbaum A, Shemesh J, Fisman EZ, Motro M. Advanced mitral annular calcification is associated with severe coronary calcification on fast dual spiral computed tomography. Invest Radiol 2000; 35:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/48\">",
"      Atar S, Jeon DS, Luo H, Siegel RJ. Mitral annular calcification: a marker of severe coronary artery disease in patients under 65 years old. Heart 2003; 89:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/49\">",
"      Adler Y, Herz I, Vaturi M, et al. Mitral annular calcium detected by transthoracic echocardiography is a marker for high prevalence and severity of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol 1998; 82:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/50\">",
"      Kannam H, Aronow WS, Chilappa K, et al. Comparison of prevalence of &gt;70% diameter narrowing of one or more major coronary arteries in patients with versus without mitral annular calcium and clinically suspected coronary artery disease. Am J Cardiol 2008; 101:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/51\">",
"      Adler Y, Vaturi M, Fink N, et al. Association between mitral annulus calcification and aortic atheroma: a prospective transesophageal echocardiographic study. Atherosclerosis 2000; 152:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/52\">",
"      Antonini-Canterin F, Capanna M, Manfroni A, et al. Association between mitral annular calcium and carotid artery stenosis and role of age and gender. Am J Cardiol 2001; 88:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/53\">",
"      Kamensk&yacute; G, Lisy L, Polak E, et al. Mitral annular calcifications and aortic plaques as predictors of increased cardiovascular mortality. J Cardiol 2001; 37 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/54\">",
"      Barasch E, Gottdiener JS, Marino Larsen EK, et al. Cardiovascular morbidity and mortality in community-dwelling elderly individuals with calcification of the fibrous skeleton of the base of the heart and aortosclerosis (The Cardiovascular Health Study). Am J Cardiol 2006; 97:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/55\">",
"      Benjamin EJ, Plehn JF, D'Agostino RB, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 1992; 327:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/56\">",
"      Kizer JR, Wiebers DO, Whisnant JP, et al. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke 2005; 36:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/57\">",
"      Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001; 87:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/58\">",
"      Rodriguez CJ, Bartz TM, Longstreth WT Jr, et al. Association of annular calcification and aortic valve sclerosis with brain findings on magnetic resonance imaging in community dwelling older adults: the cardiovascular health study. J Am Coll Cardiol 2011; 57:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/59\">",
"      Eicher JC, Soto FX, DeNadai L, et al. Possible association of thrombotic, nonbacterial vegetations of the mitral ring-mitral annular calcium and stroke. Am J Cardiol 1997; 79:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/60\">",
"      Lin CS, Schwartz IS, Chapman I. Calcification of the mitral annulus fibrosus with systemic embolization. A clinicopathologic study of 16 cases. Arch Pathol Lab Med 1987; 111:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/61\">",
"      Shohat-Zabarski R, Paz R, Adler Y, et al. Mitral annulus calcification with a mobile component as a possible source of embolism. Am J Geriatr Cardiol 2001; 10:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/62\">",
"      Eicher JC, De Nadai L, Soto FX, et al. Bacterial endocarditis complicating mitral annular calcification: a clinical and echocardiographic study. J Heart Valve Dis 2004; 13:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/63\">",
"      Vistarini N, d'Alessandro C, Aubert S, et al. Surgery for infective endocarditis on mitral annulus calcification. J Heart Valve Dis 2007; 16:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/64\">",
"      Fox CS, Guo CY, Larson MG, et al. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol 2006; 97:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/65\">",
"      Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/66\">",
"      Sengupta PP, Mohan JC, Mehta V, et al. Accuracy and pitfalls of early diastolic motion of the mitral annulus for diagnosing constrictive pericarditis by tissue Doppler imaging. Am J Cardiol 2004; 93:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/67\">",
"      Hill EE, Herijgers P, Claus P, et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J 2007; 154:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/68\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/69\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/70\">",
"      Feindel CM, Tufail Z, David TE, et al. Mitral valve surgery in patients with extensive calcification of the mitral annulus. J Thorac Cardiovasc Surg 2003; 126:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/71\">",
"      d'Alessandro C, Vistarini N, Aubert S, et al. Mitral annulus calcification: determinants of repair feasibility, early and late surgical outcome. Eur J Cardiothorac Surg 2007; 32:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/58/37801/abstract/72\">",
"      Papadopoulos N, Dietrich M, Christodoulou T, et al. Midterm survival after decalcification of the mitral annulus. Ann Thorac Surg 2009; 87:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8122 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37801=[""].join("\n");
var outline_f36_58_37801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Caseous calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tricuspid annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Conduction system disease and bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mortality and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      IMPACT ON ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Quantification of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Impact on tissue Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Detection of mitral valve abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Risk factor modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Arrhythmia therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8122|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/36/12864\" title=\"diagnostic image 1\">",
"      MAC long-axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/26/11680\" title=\"diagnostic image 2\">",
"      MAC short-axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/42/21154\" title=\"diagnostic image 3\">",
"      Apical 4C echo MAC and TAC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/0/37890\" title=\"diagnostic image 4\">",
"      Doppler MV MAC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/21/35154\" title=\"diagnostic image 5\">",
"      Apical 2C echo MAC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/38/1633?source=related_link\" title=\"calculator 1\">",
"      Calculator: Atrial fibrillation CHADS(2) score for stroke risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_58_37802="Nodular type MCL";
var content_f36_58_37802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Nodular type of mantle cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular type of mantle cell lymphoma shows multiple nodules with irregular margins. Hematoxylin and eosin, 10x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37802=[""].join("\n");
var outline_f36_58_37802=null;
var title_f36_58_37803="Aortic dissection anatomy based clinical findings";
var content_f36_58_37803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Presentations of aortic dissection based on affected structures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Artery or structure involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic insufficiency or heart failure",
"       </td>",
"       <td>",
"        Aortic valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"       <td>",
"        Coronary artery (often right)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac tamponade",
"       </td>",
"       <td>",
"        Pericardium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemothorax",
"       </td>",
"       <td>",
"        Thorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke or syncope",
"       </td>",
"       <td>",
"        Brachiocephalic, common carotid, or left subclavian arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper extremity pulselessness, hypotension pain",
"       </td>",
"       <td>",
"        Subclavian artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraplegia",
"       </td>",
"       <td>",
"        Intercostal arteries (give off spinal and vertebral arteries)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower extremity pain, pulselessness, weakness",
"       </td>",
"       <td>",
"        Common iliac artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain; mesenteric ischemia",
"       </td>",
"       <td>",
"        Celiac or mesenteric arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Back or flank pain; renal failure",
"       </td>",
"       <td>",
"        Renal artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Horner syndrome (ptosis, miosis, anhidrosis)",
"       </td>",
"       <td>",
"        Superior cervical sympathetic ganglion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37803=[""].join("\n");
var outline_f36_58_37803=null;
var title_f36_58_37804="Treatment of conjunctivitis";
var content_f36_58_37804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapy of conjunctivitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Empiric approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin ophthalmic ointment",
"       </td>",
"       <td>",
"        1/2\" four times daily for 5 to&nbsp;7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymyxin-trimethoprim drops",
"       </td>",
"       <td>",
"        1 to 2 drops four times daily for 5 to 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Specific approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Bacterial conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Erythromycin ophthalmic ointment",
"       </td>",
"       <td>",
"        1/2\" four times daily for 5 to 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Polymyxin-trimethoprim drops",
"       </td>",
"       <td>",
"        1 to 2 drops four times daily for 5 to 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fluoroquinolone ophthalmic drops (preferred agent in contact lens wearers)",
"       </td>",
"       <td>",
"        Generally, 1 to 2 drops four times daily for 5 to 7 days (regimens vary by medication)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Azithromycin drops",
"       </td>",
"       <td>",
"        1 drop twice a day for 2 days; then 1 drop daily for 5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Viral conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        OTC antihistamine/decongestant drops",
"       </td>",
"       <td>",
"        1 to 2 drops four times daily PRN for no more than&nbsp;three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Allergic conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        OTC antihistamine/decongestant drops",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 drops four times daily PRN for no more than&nbsp;three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Mast cell stabilizer/antihistamine drops",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 drops three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Non-specific conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Eye lubricant drops",
"       </td>",
"       <td>",
"        1 to 2 drops Q 1 hr - four times daily PRN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         AND/OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Eye lubricant ointment",
"       </td>",
"       <td>",
"        1/2\" QHS or four times daily PRN",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     QHS: at bedtime.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37804=[""].join("\n");
var outline_f36_58_37804=null;
var title_f36_58_37805="Diaphragm PI";
var content_f36_58_37805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo depicts a contraceptive diaphragm. The diaphragm in this photo (with a hole) is used for fitting; the diaphragm a woman uses will not have a hole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37805=[""].join("\n");
var outline_f36_58_37805=null;
var title_f36_58_37806="ECX for advanced esophagogastric cancer";
var content_f36_58_37806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epirubicin, cisplatin, and capecitabine (ECX) for advanced esophagogastric cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Epirubicin",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer into a free flowing IV solution with normal saline (NS)*, generally over 3 to 20 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with at least 250 mL NS and administer over 120 minutes. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Capecitabine",
"        </strong>",
"       </td>",
"       <td>",
"        625 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per dose by mouth",
"       </td>",
"       <td>",
"        Twice daily; take with water within 30 minutes after a meal.",
"       </td>",
"       <td>",
"        Days 1 through 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Give IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Epirubicin plus cisplatin: HIGH. Oral capecitabine alone: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There are no recommended premedications to prevent infusion reactions. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Epirubicin is a vesicant; cisplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of febrile neutropenia with ECX was 0 and 7 percent in two trials",
"        <sup>",
"         [1,2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. In the original ECX protocol, patients were required to have GFR &ge;60 mL/min and a serum creatinine within normal range",
"        <sup>",
"         [2]",
"        </sup>",
"        . Lower starting doses of capecitabine may be needed in patients with renal impairment",
"        <sup>",
"         [3]",
"        </sup>",
"        . Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment",
"        <sup>",
"         [4]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. In the original protocol, patients were excluded from receiving epirubicin if their LVEF was below the normal range",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count on day 1 prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel including creatinine and liver function tests on day 1 prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for stomatitis, diarrhea, and palmar-plantar erythrodysesthesiass during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative epirubicin dose. Reassess LVEF periodically as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Hold epirubicin until the platelets are &ge;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the absolute neutrophil count is &ge;1500 cells/mm",
"        <sup>",
"         3[4]",
"        </sup>",
"        . In the original ECX protocol, cisplatin and epirubicin doses were delayed by one week or until myelosuppression was resolved if the platelet count was &lt;100,000/microL or the total white blood cell count was &lt;2000 cells/microL on day 1",
"        <sup>",
"         [2]",
"        </sup>",
"        . The dose of epirubicin was reduced by 25 percent for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. There were no dose reductions for capecitabine based on blood counts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal dysfunction:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL",
"        <sup>",
"         [5]",
"        </sup>",
"        . In the original trial of ECX, full dose cisplatin was given if the estimated GFR was &gt;60 mL/min, and the drug was held if the estimated GFR was &lt;40 mL/min",
"        <sup>",
"         [2]",
"        </sup>",
"        . For an estimated GFR of 40 to 60 mL/min, the dose of cisplatin (in mg) was equivalent to the estimated GFR (in mL/min).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis, diarrhea, nausea and vomiting:",
"        </strong>",
"        In the original trial of ECX, capecitabine was stopped for grade 2 to 3 stomatitis, diarrhea, or nausea and vomiting",
"        <sup>",
"         [2]",
"        </sup>",
"        . If grade 3 toxicity was controlled adequately within two days and after resolution of any grade 2 toxicity, capecitabine was continued at full dose. If grade 2 toxicity occurred a second time, the dose was reduced by 25 percent; a third time, by 50 percent, and if it occurred a fourth time, treatment was discontinued. If grade 3 toxicity took longer than two days to resolve, the capecitabine dose for the next cycle was reduced by 25 percent; if grade 3 toxicity recurred, the dose was reduced by 50 percent, and if it recurred, the drug was discontinued. For grade 4 mucositis, diarrhea, or nausea or vomiting, the drug was either discontinued or the dose reduced by 50 percent. Doses of capecitabine that are omitted for toxicity are not replaced or restored. Instead, the patient should resume the planned treatment cycles at the modified dose",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. If neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesias:",
"        </strong>",
"        In the original trial, capecitabine was withheld for grade 2 or worse palmar-plantar erythrodysesthesias until resolution and the subsequent doses reduced by 15 percent for grade 2, 30 percent for grade 3, and 50 percent for grade 4 toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Hold epirubicin until all non-hematologic toxicity resolved to &le; grade 1",
"        <sup>",
"         [4]",
"        </sup>",
"        . Reduce epirubicin dose by 25 percent for any grade 3/4 non-hematologic toxicity in previous cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cunningham D, et al. N Engl J Med 2008; 358:36.",
"      </li>",
"      <li>",
"       Sumpter K, et al. Br J Cancer 2005; 92:1976.",
"      </li>",
"      <li>",
"       Capecitabine. FDA-approved manufacturer's product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Epirubicin hydrochloride injection. FDA-approved manufacturer's product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection. FDA-approved manufacturer's product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37806=[""].join("\n");
var outline_f36_58_37806=null;
var title_f36_58_37807="CNS tumor child site";
var content_f36_58_37807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of all childhood primary brain and CNS tumors (0-19 yr) by site CBTRUS 2000-2004 (n = 5873)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: CBTRUS (2008) Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Published by the Central Brain Tumor Registry of the United States.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_58_37807=[""].join("\n");
var outline_f36_58_37807=null;
